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1. Chapter I: Introduction 
1.1. Drug Delivery Technology  
Nanotechnology can be defined as “the design, characterization, production and 
application of materials, devices and systems by controlling shape and size of the 
nanoscale” [1]. There is no single field of nanotechnology. The term broadly refers to 
fields such as biology, physics, chemistry, and any others involved in the controlled 
manipulation, measurement and production of materials and devices at the nanoscale 
order, characterized by new proprieties and functions [2]. Particular interest in 
nanotechnology is in the healthcare area, where nanomedicine has emerged as a new 
research field, which could have deep effect in the current treatment of various diseases. 
Nanomedicine is defined as the application of nanotechnology to healthcare [3]. Within 
nanomedicine, drug delivery systems (DDS) have assumed an important role in the past 
three decades, and significant advances have been made in this multidisciplinary field 
due to the necessity to develop new therapeutic strategies. Indeed, the aim of DDS are 
hence the maximization of the therapeutic efficacy, minimization of the adverse effects 
of the drugs of interest and the delivery of drugs in controlled manner [4]. The 
conventional pharmaceutic preparations, and the common drugs administration routes 
(e.g. oral, parenteral, subcutaneous, intravenous, intramuscular, topical, etc.) suffer from 
some problems that can be summarized in three main points: (a) typically drugs are 
administered at determined intervals, in order to maintain the therapeutic effects. The 
time between each administration causes a drop of drug concentration in the body that 
results toxic and affects the therapeutic benefits (Figure 1), (b) many therapeutically 
compounds are destroyed by the regular defense mechanisms of the body before they 
arrive at target sites, (c) the eukaryotic cells are characterized by bilayer lipid membrane, 
that represents for the drugs a barrier to overcome in order to get their effects.   
 
 
Figure 1: Drug plasma level concentrations obtained with conventional administration and 
controlled drug release [5]. 
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In order to solve these problems, novel DDS are designed to encapsulate therapeutic 
agents, with the purpose of achieving the follow advantages: 
 improved delivery of poorly water-soluble drugs;  
 targeted delivery of drugs in a specific manner;  
 delivery of large macromolecule drugs to intracellular sites of action;  
 co-delivery of two or more drugs or therapeutic modality for combination 
therapy;  
 potentially decrease the amount of drug to administer, thus reducing the side 
effects; 
 allow the administration of non conventional drugs; 
The first device used as DDS was described in the 1960s as lipid vesicles, that later 
became known as liposomes [6]. Afterwards, a variety of other organic and inorganic 
biomaterials for DDS were developed. In the 1980s the first examples of cell specific 
targeting of liposomes were described, and after more complex DDS were found able to 
responding to specific conditions, such as changes in pH or temperatures, to trigger drug 
release [7]. To date there are more than twenty nanotechnology therapeutic products that 
have been approved by the Food and Drug Administration (FDA) for clinical use, and 
more are in clinical trial [8]. Among DDS, the formulation of nanosized drug delivery 
devices have become an important area of research, because they have the ability to 
deliver a wide variety of drugs such as proteins, peptides, DNA and RNA, to several 
areas of the body for sustained periods of time.  
The characteristics of DDS depend on the nature of the materials that constitute the 
delivery system. Organic macromolecules have highly tunable physical-chemical 
characteristics and in some cases, polymeric materials can be further processed or 
functionalized [9]. For this reason, at present, the main class of DDS is represented by 
polymeric based systems; however the promising applications of nanomedicine are not 
limited to drug delivery, but include also in vitro diagnostics, in vivo imaging and tissue 
engineering. Some of these fields are becoming realities or are actually being used today, 
while others are generating promise in their early phases of development and are 
expected to experience vigorous growth in the future. As recognition of the importance 
of these fields, it is expected that the global market of nanoscale applications in the 
medical field could grow to $70-160 billion by 2015 [10].  
 
1.1.1. Polymeric Biomaterials  
A biomaterial can be defined as “any matter, surface, or construct that interacts with 
biological systems” [11]. The study of these materials is called biomaterials science and 
include science fields like medicine, biology, chemistry and tissue engineering. The 
important prerequisite to qualify a material as a biomaterial is that it should be 
biocompatible. Biocompatibility is the capability of materials to coexist with living 
tissues or organisms without producing toxicity, injury, or immunological response [12]. 
Consequently, a wide range of materials encompassing all the classical materials such as 
metals, ceramics, glasses, and polymers have been investigated as biomaterials. Among 
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these, polymers are the most versatile class of biomaterials that have been extensively 
investigated for medical and related applications [13]. The use of polymeric materials as 
biomaterials has evolved over the past decades and their use in medicine dates back 
almost to the birth of the of polymer science. The combination between advanced 
organic chemistry and polymer synthesis has led to the development of tools for the 
design of polymer architecture and the grafting of bioactive molecules. In this way, 
polymers offer the advantage, compared with other types of biomaterials, such as metals 
and ceramics, to be engineered and processed in different manners in order to allow 
unique chemical structures with specific functions for desired applications [14]. The 
employ of polymeric biomaterials has found a multitude of uses, especially as drug 
delivery systems and tissue engineering scaffolds. Drug delivery systems, as described in 
section 1.1, are a tool to administrate pharmaceutical agents in order to improve their 
therapeutic effect. The role of polymers in drug delivery covers multiple aspects, from 
the enhancement of the physical-chemical stability of the drug to the regulation of drug 
release and targeting. In fact, the use of polymers as drug delivery carriers allows the 
controlled release of the drug, creates easier dosage regimes that consequently improve 
the absorption, distribution and the elimination of the drug. Many active agents such as 
proteins, antibody, vaccine and gene based drugs, may not be delivered using common 
administrations routes and polymers are currently used as physical carriers for these 
drugs [15].  
Tissue engineering has emerged as an interdisciplinary field that applies the principles of 
engineering and life sciences toward the development of tissue substitutes or maintaining 
tissues and organs functions [16]. Indeed, tissue engineering purposes involve 
replacement or repair of damaged or failed tissues with viable ones by creation of an 
environment, which promotes the native capacity of cells to integrate, differentiate and 
proliferate. Even in this field, polymers offer a number of advantages, over other 
materials in scaffold preparations, such as the obtainment for the desiderate degradation 
kinetics and the possibility to fabricate different shapes with desired pore morphologic 
features. Furthermore, polymers can be designed with chemical functional groups that 
can induce tissue growth and their regeneration [17].  
Biodegradable polymers, used in both drug delivery and tissue engineering, can be 
generally classified as natural and synthetic, based on their origin. Natural polymers 
seem to be the obvious choice for biomedical applications due to their excellent 
biocompatibility, as structurally they closely mimic native cellular environments, have 
unique mechanical properties, and are biodegradable by an enzymatic or hydrolytic 
mechanism. However, natural polymers suffer from a number of disadvantages, such as 
risk of viral infection, antigenicity, sourcing and processing that could generate variation 
in properties from batch to batch [18]. Synthetic polymers, on the other hand, offer 
ample advantages due to their synthetic flexibility and the possibility to develop 
polymers having a wide spectrum of properties with excellent reproducibility. 
Furthermore, the controlled degradation rate of these polymers is easier to reach due to 
the possibility to vary their structure. The fields of application of synthetic and natural 
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polymeric biomaterials is not only limited to drug delivery and tissue engineering, but is 
indeed very wide, including surgical field, implant materials and in a large numbers of 
medical devices, such as in dental, orthopedic, dermatological, ophthalmic and 
cardiovascular applications [19]. Moreover, a large interest come from the concept of 
“smart” polymers originated from the ability of certain synthetic polymers to mimic the 
response of physiological polymers such as DNA and proteins. In fact, the “smart” 
polymers have the capability to change according to their surrounding environment 
because can be sensitive to a large number of factors such as temperature, humidity, pH, 
intensity of light and change in electrical or magnetic field [20]. Biomedical polymers 
classification and their main applications are summarized in Table 1[21] [22] [23].   
TABLE 1: Synthetic and natural polymers classification and applications in 
DDS. 
Synthetic polymers 
Polymer Main applications 
Poly (glycolic acid); 
Poly (lactic acid) and 
their copolymers 
Used in sutures, drug delivery systems and tissue engineering. 
Copolymerized to regulate degradation time. 
Polyhydroxybutyrate Biodegradable, used as matrix for drug. 
Poly (caprolactone) and 
copolymers 
Delivery systems, cell microencapsulation. 
Poly(alkylene succinate) 
Properties can be tuned by chemical modification, 
copolymerization and blending. 
Polyanhydrides 
Biodegradable, useful in tissue engineering and for the release 
of bioactive molecules. 
Poly(ortho esters) 
Surface–eroding polymers. Application in sustained drug 
delivery, ophthalmology. 
Polycyanoacrylates 
Biodegradable, depending on the length of the alkyl chain. Used 
as surgical adhesives, glues, and in drug delivery. 
Polyacrylonitrile Dialysis membranes. 
Polyphosphazenes 
Can be tailored with versatile side–chain functionality. 
Applications in drug delivery. 
Polyamides 
Used for sutures and hemofiltration membranes. Inhibitors of 
DNA transcription. 
Polyurethanes 
Used for prostheses, vascular grafts, catheters tissue adhesives, 
artificial cardiac structures, coatings. 
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Polypropylene Membrane plasmapheresis, sutures, external medical devices. 
Polyethylene Used for orthopaedic implants and catheters. 
Poly(methyl 
methacrylate) 
This and its copolymers are used as dental implants, in bone 
replacement and as intraocular lenses. 
Poly(hydroxyethyl 
methacrylate) 
Used for contact lenses, ocular prostheses, skin coatings, 
catheters. 
Polytetrafluoroethylene 
(Teflon®) 
Used for vascular grafts, clips and sutures facial prosthesis, 
coatings. 
Polydimethylsiloxanes 
Used for implants in plastic surgery, orthopedics, blood bags, 
pacemakers, drug delivery devices, membrane oxygenators. 
Poly(N-vinyl 
pyrrolidone) 
Hydrogels for controlled release of drugs from metal stents, or 
in blood substitutes. 
Polysulfone Heart valves, penile prostheses. 
Polyvinyl chloride Used for tubing, blood bags. 
Polystyrene Used as substrates for cell cultures. 
Poly(ethylene oxide) 
Different polymer derivatives and copolymers used in a variety 
of biomedical applications. 
Poly (ethylene glycol) 
Several applications as spacer, in bioconjugations, coatings, 
excipient in many pharmaceutical products. 
Polylysine Applied in gene delivery, formation of conjugate vectors. 
Polyethylenimine Applied in gene delivery, formation of conjugate vectors. 
Polyamidoimine Vectors of nucleotide transfer and gene delivery. 
Natural polymers 
Polymer Main applications 
Proteins and protein-base polymers 
Collagen Sutures, drug release. 
Gelatin Used in the preparation of gels and in drug release. 
Albumin Drug stabilizer and drug release. 
Polysaccharides and vegetal derived polymers 
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Carboxymethylcellulose 
Drug release, dialysis membranes, cell immobilization 
(ionotropic gelation and formation of polyelectrolyte 
complexes). 
Starch Drug delivery. 
Cellulose sulphate In polyelectrolytic complexes for imunoisolation. 
Agarose Used in clinical analysis and as matrix. 
Alginate 
Biocompatible. Applied in gel preparation and to immobilize 
cell matrix and enzymes. For the release of bioactive molecules, 
injectablem icrocapsules for neurodegenerative diseases and 
hormones deficiency. 
Polysaccharides and human/animal derivatives 
Hyaluronic acid 
Moisturizing agent, wound dressing, artificial tears in 
ophthalmology, various orthopaedic applications. 
Heparin and 
glycosaminoglycans 
Thrombolytic anticoagulant properties. Used in surgery for 
ionotropic gelation and in capsules preparation. 
Microbial Polysaccharides 
Dextran and derivatives 
Excellent reological properties, plasma expander. Used in drug 
delivery. 
Chitosan and derivatives 
Produced generally by partial deacetylation of chitin. 
Polycationic polymer. Biocompatible, not toxic. Used in gel and 
film preparation. Applied in drug delivery. 
 
1.1.2. Polymer Drug Delivery Systems 
Polymeric systems are the most versatile class of materials and have an enormous impact 
on pharmacological therapy. In recent years both natural and synthetic polymers have 
been investigated as carriers for controlling drug release. The first generation DDS were 
based on non degradable polymers matrix, although the disadvantage of this systems was 
that the release kinetics was incontrollable and totally dependent of the diffusive 
behavior of the drug through the polymer matrix [24]. The second generation of DDS, 
based on natural or synthetic biodegradable polymers, allowed the controlled release of 
the encapsulated drug and the possibility to address the active agents to the target site. 
The choice of the polymer is a key point to achieve a controlled release, because the 
properties of the DDS depend on the physical, chemical and biological proprieties of 
their constituents. The polymer matrix can be engineered in order to target a selected 
tissue and to obtain the precisely modulated release kinetic [25]. Nowadays, a third 
generation of DDS is under investigations. These systems can be design by multi 
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component materials specifically engineered to avoid biological barriers and stimulate 
cellular responses such as direct cell proliferation and differentiation [26].  
Based on the nature of the carriers, controlled drug delivery devices can be classified 
into two main categories: diffusion controlled release systems and degradable delivery 
systems. In diffusion controlled release systems, the active agent release within an 
aqueous solution is inhibited by the insoluble polymer matrix. The drug is released either 
by passing through the pores or between polymer chains, and these are the processes that 
control the release rate. Diffusion controlled systems are of two types: reservoir 
(membrane systems) and matrix systems (Figure 2).  
 A reservoir is generally spherical, cylindrical or dislike in shape and consists of 
a drug core in powdered or liquid form surrounded by a polymeric film. This 
layer of non-biodegradable polymeric material represents the only barrier 
through which the drug slowly diffuses. The proprieties of the drug and the 
polymer govern the diffusion rate of the drug release. The reservoir can be a 
microporous or macroporous polymer film. Its composition changes from one 
component to a mixture of polymers, or to a heterogeneous matrix in which 
hydrophilic polymer particles are dispersed in a hydrophobic polymer matrix 
[27].  
 In the matrix type of diffusion control system, the drug is uniformly distributed 
throughout the polymer matrix and is released from the matrix at a uniform rate 
as drug particles dislodge from the polymer network. Drugs can be physically 
embedded in polymers at large enough concentrations to create a series of 
interconnecting pores through which the drug can slowly diffuse. In these 
systems, the matrix may consist of hydrophobic or viscous hydrophilic 
polymers in which the solid drug is dispersed. These release systems are cheap 
and readily available, since they are prepared simply by mixing the polymer 
matrix and the drug. The release rate is based on the diffusion of the drug 
molecules to the device surface where they are delivered. This process takes 
place as long as the higher concentration of the drug in the system core affords 
a constant flow of drug molecules through the matrix. In this dissolution-
diffusion process, the interface between the drug reservoir and the release 
moiety progressively moves towards the core of the device [28]. 
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Figure 2: A schematic representation of the reservoir and matrix DDS. In membrane 
DDS, the drug is contained in a core, which is surrounded by a polymer membrane, and 
it is released by diffusion through this rate-controlling membrane. Reservoir devices 
have a coating that controls the release rate (modified from [24]). 
In degradable delivery systems the drug molecules, which are initially dispersed in the 
polymer, are released as the polymer starts eroding or degrading. Similar to the reservoir 
system, the degradable reservoir system has a drug-loaded core surrounded by a polymer 
coating that degrades or erodes. These systems combine the advantage of long-term 
constant rate drug release with bioerodability or biodegradability. Polymer surface and 
bulk degradation are two typical modes of degradations. In a surface-degrading polymer, 
degradation is confined to the outer surface of the device. In a bulk-degrading polymer, 
however, degradation occurs homogeneously throughout the material. Water is an 
important factor during hydrolysis and thus water intrusion into the device is of 
significant importance for the study of degradation kinetics as well as release kinetics 
[29]. The use of these systems avoids the problems related to the physiological excretion 
or mechanical removal of the non degradable drug delivery devices after their function is 
completed. In general, an almost constant release profile over long periods can be 
achieved by fine modulation of geometric, chemical, degradation, and porosity 
characteristics of the device. In this respect, degradable drug delivery systems can be 
formulated in different shapes, i.e. cylinders, sticks, microcapsules, microspheres, fibers, 
films, and nanoparticles [30].   
1.1.3. Polymeric Nanoparticles  
Polymeric nanoparticles (NPs) have been extensively studied as drug carriers in the 
pharmaceutical field. NPs are frequently defined as solid, colloidal particles in the range 
10-1000nm with the capability to carry drugs to the target site or release drugs in a 
controlled way in the body [31]. The first generation of particulate DDS was primarily 
based on liposomes and polymer-drug conjugates. Liposomes, discovered in the 1960s, 
can be defined as a spherical vesicle with a lipid bilayer membrane structure, which can 
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encapsulate both hydrophilic and hydrophobic drugs [32]. Polymer-drug conjugates, 
where the drug or bioactive compound is covalently linked to the macromolecular 
backbone, first appeared in 1970s and also have been extensively investigated [33]. Both 
liposomes and polymer-drug conjugates have provided the foundations for the field of 
advanced drug delivery based on nanotechnology. However, these systems are 
characterized by several disadvantages, such as poor encapsulation efficiency and 
bioavailability of drugs, difficulty to address the systems to target site and high 
production cost. Nowadays, the development of NPs based on polymeric materials, 
offers the tools for overcoming these barriers. Indeed, polymeric NPs systems offer the 
capability to achieve controlled release of the drugs, improve the stability of active 
agents (the polymeric shell protects the drugs against degradation factors such as pH, 
enzymes, light) and their subcellular size allows relatively higher intracellular uptake 
than other particulate systems. Other advantages of NPs as active substance carriers 
include high drug encapsulation efficiency, low polymer content compared to other DDS 
and the possibility to synthesized NPs from materials that are either biocompatible or 
biodegradable [34]. The term NPs is a collective term given for any type of polymeric 
NPs. According to the structural organization, NPs can be classified as nanocapsules and 
nanospheres. Polymeric nanospheres may be defined as a matrix particles whose entire 
mass is solid and molecules may be adsorbed at the sphere surface or encapsulated 
within the particle. Polymeric nanocapsules are vesicular systems, acting as a kind of 
reservoir, in which the entrapped drugs are confined to a cavity consisting of a liquid 
core (either oil or water) surrounded by a solid polymer shell [35]. A schematic 
representation of nanosphere and nanocapsules is shown in Figure 3.  
 
 
Figure 3: Structure of nanocapsules and nanospheres [36].  
The design of polymeric NPs depends on the therapeutic application, target site (organs, 
tissues, cellular or subcellular organelles) and the route of administration. Although 
injection is the most common way of delivering NPs, these nanocarriers can be also 
delivered through the skin, oral, nasal, pulmonary, vaginal, rectal, ocular and buccal 
routes [37]. In every routs of administration, NPs have to be able to allow their delivery 
beyond the different biological barriers, such as skin, mucus, blood, extracellular matrix, 
and cellular or subcellular barriers. With respect to these factors, the proper selection of 
the polymers drastically affect the NPs intracellular fate, safety, biocompatibility, release 
kinetics and the capability to overcome biological barriers [38]. Biocompatibility and 
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biodegradability of NPs are essential for the safety of patients and should be tested both 
in vitro and in vivo. These restrictions are firm with systemic administration of NPs, 
whereas they are less significant for NPs designed for topical applications. The use of 
biodegradable materials avoids the problems related to the physiological excretion or 
mechanical removal of the delivery device after drug depletion. The presence of a 
biodegradable matrix can provide a further control of the release rate, by joining the 
typical diffusive mechanism with tunable polymer degradation [39].  
The most commonly used biodegradable polymers are poly (lactic acid) (PLA), poly 
(glycolic acid) (PGA), poly (ε-caprolactone) (PCL) and the copolymer poly (lactic-co-
glycolic acid) (PLGA) of PLA and PGA. Other than these polymers, natural hydrophilic 
polymers, such as chitosan, sodium alginate and gelatin have also been used to prepare 
drug loaded NPs. However, the aliphatic polyesters based on lactic and glycolic acids are 
unquestionably the most widely employed polymers and are approved by the FDA for 
human use [40]. Their high biodegradability and biocompatibility are well assessed. In 
fact, it is known that lactide/glycolide polymer chains are cleaved by hydrolysis to form 
natural metabolites (lactic and glycolic acids), which are eliminated from the body 
through the Krebs cycle [41].  
Polymeric NPs are being developed to improve the diagnosis and treatment of a wide 
range of diseases, ranging from cancer, viral infections, cardiovascular diseases to 
pulmonary and urinary tract infections. A growing number of applications are still under 
investigation in order to integrate polymer science with molecular cell biology, both for 
developing new approaches to human therapies and as basic tools in biological and 
medical research [42]. 
1.1.3.1. Nanoparticles Preparation Technique 
The properties of NPs have to be optimized according to the particular application. In 
order to achieve the properties of interest, the method of preparation plays a key role. 
Thus, it is highly advantageous to have several preparation techniques to obtain NPs 
with the desired properties. The choice of preparation method is made on the basis of a 
number of factors such as the type of polymeric system, area of application, size 
requirement, etc. For instance, a polymeric system that is developed for an application in 
the biomedical or environmental fields should be completely free from additives or 
reactants such as surfactants or traces of organic solvents. In addition, the preparation 
process should guarantee for the chemical stability and biological activity of the 
incorporated drug. There are several methods for the preparation of NPs:  
 Emulsion/Solvent Evaporation: this is the most common method used for the 
preparation of NPs. The preparation of nanocarriers follows the general 
protocol of dissolving the polymer in a water immiscible, volatile organic 
solvent which is then emulsified with an aqueous phase to stabilize the system. 
The organic solvent is then evaporated inducing the formation of polymer 
particles from the organic phase droplets. This technique has been successful 
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for encapsulating hydrophobic drugs. However, results for incorporation of 
hydrophilic bioactive agents are yet poor. A modification of this procedure has 
led to protocols that favor the encapsulation of hydrophilic compounds, the 
single oil-in-water emulsion (o/w) and the double (water-in-oil)-in-water, 
(w/o/w) emulsion techniques [43]. In the single emulsion method, the drug and 
the polymer are dissolved in an organic solvent and the resulting solution is 
added into an aqueous solution to make an o/w emulsion with the aid of 
amphiphilic macromolecules such as surfactant. The solvent in the emulsion is 
removed by evaporation, resulting in formation of compact NPs. In the double 
emulsion technique, a primary emulsion is prepared by dispersing the aqueous 
phase into an organic solvent containing a dissolved polymer. This is then 
reemulsified, under vigorous stirring, in an outer aqueous phase containing a 
stabilizer, thus forming a w/o/w emulsion. The emulsifications are carried out 
using either high speed homogenizers or sonicators. The w/o/w emulsion 
system has been used widely for the development of protein delivery systems. 
Both in single and double emulsions, several parameters can influence the 
properties of the particles produced, such as nature of polymer, polymer 
molecular weight and stirring speed. The main drawback of these methods is 
the removal of excipients post production. Any residual organic solvents will 
have toxicological implications. Another limitation is that surfactant must be 
present for preparation of nanoparticles in order to stabilize the system [44].  
 Salting Out: is an emulsion-based approach, with the advantages that avoids 
surfactants and chlorinated solvents. In brief, a saturated salt solution 
containing a stabilizing agent such as polivinilalcool (PVA) is added under 
stirring to an acetone solution of the polymer. An o/w emulsion forms as the 
salt prevents the water and acetone mixing. Sufficient water is then added to 
allow the acetone to diffuse into the external aqueous phase and induce NPs 
formation. From the perspective of drug encapsulation, this method is most 
appropriate for water insoluble drugs, although the loading of water soluble 
drugs can be possible by altering the pH of the aqueous phase. However, a 
limitation of this method is represented by the presences of salts, because their 
presence affects the stability of many bioactive agents, such as proteins and 
peptides [45].  
 Phase separation: this method involves the phase separation of a polymer 
solution by adding an organic non-solvent. Drugs are first dissolved in a 
polymer solution. An organic non-solvent is added to this solution (e.g. silicon 
oil, vegetable oil, light liquid paraffin) under continuous stirring, by which the 
polymer solvent is gradually extracted and soft coacervate of droplets 
containing the drug are generated. The rate of adding non-solvent affects the 
extraction rate of the solvent, the size of the particles and encapsulation 
efficiency of the drug. The coacervate phase is then hardened by exposing it 
into an excess amount of another non-solvent such as hexane, heptane, and 
diethyl ether. The final characteristics of the colloidal products are affected by 
the molecular weight of the polymer, viscosity of the non-solvent, and polymer 
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concentration. The main disadvantage of this method is a high possibility of 
forming large aggregates. Extremely sticky coacervate droplets frequently 
adhere to each other before complete phase separation. This technique is 
promising for the preparation of protein-loaded microcapsules [46].  
 Nanoprecipitation: the basic principle of this technique is based on the 
interfacial deposition of a polymer, dissolved in a semi-polar solvent (i.e., 
ethanol, acetone, hexane, methylene chloride or dioxane), into an aqueous, non-
solvent solution, under moderate stirring. Acetone is the most frequently 
employed polymer solvent in this method. Sometimes, binary solvent blends, 
acetone with small amount of water, blends of acetone with ethanol and 
methanol are used. In this method, the NPs are obtained as a colloidal 
suspension that forms when the semi-polar solvent phase is added slowly to the 
aqueous phase. The advantage of this method is that it does not require 
sonication or very high temperatures conditions that might damage the active 
agents. However, this technique is mostly suitable for compounds having a 
hydrophobic nature, but displays very limited solubility in water. In order to 
overcome this barrier, modifications of this technique are under investigation to 
improve the versatility of the nanoprecipitation, particularly with respect to the 
encapsulation of hydrophilic drugs [47]. 
 Co-precipitation method: the co-precipitation method is an original and 
straightforward procedure developed by the research group where this PhD 
thesis has been carried out. It is particularly advantageous for the loading of 
protein drugs into a polymer matrix. In this case, the polymer is dissolved in a 
water/miscible organic solvent and added dropwise to an aqueous solution 
containing the selected protein and appropriate stabilizers. During the co-
precipitation process, the polymeric material gives rise to micro-phase 
separation because of its low water solubility and the concurrent interaction 
with protein molecules leads to NPs formation. Indeed, this methodology does 
not entail the use of chlorinated solvents and it does not require vigorous shear 
mixing, preventing appreciable denaturation of the entrapped protein molecule 
that typically occurs with other techniques [48].  
 Dialysis Method: the dialysis method is a simple and effective preparation 
method for small and narrow size distributed NPs. In this method, polymer is 
dissolved in an organic solvent and placed inside a dialysis tube with proper 
molecular weight cut-off. Dialysis is performed against a non-solvent miscible 
with the former miscible solvent. The displacement of the solvent inside the 
membrane is followed by the progressive aggregation of polymer due to a loss 
of solubility leading to the formation of an homogeneous suspensions of NPs. 
The solvent used in the preparation of the polymer solution affects the 
morphology and particle size distribution of the NPs [35].  
 Self Assembling: in this method NPs can be obtained by interaction between 
charged polymers and oppositely charged molecules. Such association depends 
on many factors including coulombic interactions, hydrophobicity of the 
polymer-molecule pair, and the conformational features of the polymer. 
Antonella Lisella PhD Thesis 
 
13 
 
Typically, self assembled complexes are formed by polyions with opposite 
charges. The solution behaviour of these complexes strongly depends on their 
composition. Electroneutral complexes that contain equivalent amounts of 
polyion units and monomers are water-insoluble. Nonstoichiometric complexes 
containing an excess of one of the components are generally soluble in water 
[45].   
1.1.3.2. Targeting nanoparticles  
The most prominent advantage of nanosystems as drug carrier over conventional drug 
delivery systems is the option to improve selective delivery of drugs to the site of action, 
mechanism called drug targeting. In the very general sense, drug targeting leads to the 
accumulation of therapeutic agent at the target organ or tissue in selective and 
quantitative manner, independently of the sites and routes of its administration. Ideally, 
under such conditions, the local concentration of the drug at pathological site should be 
high, while its concentration in other site should be below certain minimal levels to 
prevent side effects.  
Drug targeting can be classified into active, passive and physical targeting [49].  
Active targeting can be achieved by modification of the carriers’ surface with targeting 
moieties. In detail, antibodies or other specific adhesion molecules (e.g. polypeptides, 
oligosaccharides, viral proteins, and molecules of endogenous origin) are bound to the 
surface of NPs and antigens or other specific adhesion molecule counterparts on the 
surface of cells can be recognized. The drug should specifically be delivered to the site 
of action followed by potential intracellular uptake (Figure 4-A) [50].  
Passive targeting can be achieved without further integration of a specific targeting 
moiety on the NPs surface. This kind of targeting is generally based on the relation 
between the size and shape of the nanosystems and tissue characteristics, such as 
permeability [51]. Moreover, passive targeting occurs through different administration 
routes, for instance after intravenous application. The passive targeting through 
intravenous administration route of NPs may be achieved by extravasation in the 
diseased tissue or organ. NPs are recognized by the Reticulo Endothelial System (RES), 
mainly liver and spleen, and taken up by macrophages in the bloodstream which leads to 
fast removal from the systemic circulation. The characteristics of NPs, like size and 
surface charge, play a key role to reach efficient uptake into macrophage cells. The 
macrophage is a specialized host defense cell whose contribution to pathogenesis is well 
known. Therefore, particle uptake into those immune related cells could allow the 
selective accumulation of the NPs in inflammatory diseases [52] (Figure 4-B).  
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Figure 4: Examples of passive and active NPs targeting. (A) Passive tissue targeting by 
nanoparticles in blood vessels. Particle directed in the target tissue as a result of leaky vessels and 
ineffective lymphatic drainage; (B) Active cellular targeting of nanoparticles with conjugated 
antibodies [53]. 
 
Physical targeting can be achieved by endogenous or exogenous physical factors that can 
mediate targeted drug delivery. The targeting effect is based on the fact that pathological 
area differs from healthy area for physical parameters (e.g. temperature and pH). For 
instance, inflamed or tumor areas usually show acidosis and hyperthermia and the use of 
stimuli-responsive NPs, that disintegrate under specific pH/temperature conditions, 
allow for the releasing of the drug in the target area [54]. The physical targeting through 
exogenous factor can be achieved by the use of external physical forces, for example a 
magnetic field. For this purpose an innovative strategy consists in the administration of 
NPs with magnetic proprieties, which are able to reach the target site by applying an 
external magnetic field (Figure 5). Iron oxides are the most widely used sources of 
magnetic materials. Iron oxides have several crystalline polymorphs known as α-Fe2O3 
(hematite), β-Fe2O3, γ-Fe2O3 (maghemite), ε-Fe2O3, Fe3O4 (magnetite) and some others 
(amorphous and high pressure forms). Nevertheless, only maghemite and magnetite 
found the greatest interest for bio-applications [55]. Magnetic NPs are now widely 
studied in the field of gene and anti-cancer therapies [56]. These magnetic systems are 
also employed in medicine as an important tool in the field of diagnostic. For precise 
diagnosis of disease, many imaging modalities such as fluorescence optical imaging, 
magnetic resonance imaging (MRI), positron-emission tomography (PET), and 
computed tomography (CT) have been developed and improved with the use of magnetic 
NPs [57].  
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Figure 5: Schematic representation of physical drug targeting using magnetic NPs. NPs 
are delivered to the desired site by externally applied magnetic field. The magnetic field 
aids in particle localization and retention at targeted site by extravasation of the particles 
into the surrounding tissue (modified from [58]). 
1.2. Therapeutic Agents 
Therapeutic agents currently on the market can be placed into four categories: small 
molecules (which are chemically synthesized compounds); natural products (which are 
small, naturally occurring molecules that are generally isolated from plants, fungi); 
biotherapeutics (which are macromolecules that occur naturally or are engineered based 
on a biological template, such as proteins and peptides); and nucleic acids based 
therapeutics (which are DNA or RNA, and antisense molecule designed to treat 
infections) [59]. In the common administrations, these agents are often destroyed during 
intestinal transit or inadequately absorbed and therefore become ineffective. Moreover, 
the uncontrolled level of these agents could cause concentration spikes, thereby harming 
the body. Nanotechnology is offering solutions to these fundamental problems in the 
drug administration, in particular with the use of NPs as DDS (see section 1.1).  
1.2.1. Conventional, Chemically Synthesized Drugs 
Therapeutic agents, are prepared or synthesized by performing various chemical 
reactions using a starting material and changing its molecular structure by reactions with 
other chemicals [60]. The starting material for organic synthesis can be a simple 
compound obtained from oil and natural gas or more complex chemicals isolated in large 
amounts from plant and animal sources. Historically, most molecules aimed to treat or 
alleviate symptoms of pathological conditions, were isolated from natural products. 
However, in recent years, the necessity of developing commercially and large-scale 
production of therapeutic agents requires their chemical synthesis. Thus, the goal of 
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chemical synthesis is to supplement the supply of a drug that is commonly isolated in 
small amounts from natural sources and make these particular products commercially 
available. In the last 30 years, chemical synthesized drugs have become an integral and 
valuable part of modern medicine. Indeed, synthesized drugs have played an important 
role in the treatment of many important human diseases, such as cancer, diabetes, 
ischemic diseases and bacterial and viral infections. Moreover, these drugs have a good 
track record with patient safety and in some instances are more efficacious and safer than 
conventional medicines due to the ability to target specific molecules within the human 
body [61].  
Many anti-cancer drugs derive from chemical synthesis and have been loaded into 
nanoparticulate systems. The advantages of using polymer based nanosystems for the 
administration of anti-cancer drugs are the possibility to tune their pharmacokinetics 
according to the specific tumor treatment, gain cost-effective utilization of the 
therapeutically active species and minimize inherent toxicity to other non-targeted 
tissues [62]. The co-formulation of chemotherapeutics and adjuvant agents into 
polymeric NPs is a promising approach to achieve anticancer drug retention in tumor 
sites and maximize the effectiveness of tumor treatment [63].  
Doxorubicin, an anthracycline antibiotic, is generally administered in the form of 
hydrochloride salt intravenously. However, doxorubicin is characterized by acute side-
effects, which include nausea, vomiting, and heart arrhythmias, neutropenia (a decrease 
in white blood cells). In order to reduce its adverse effects doxorubicin was loaded into 
poly (ε-caprolactone) / polyethylene glycol poly (etherester-urethane) (PEGCL) based 
NPs. In this work, it has been demonstrated that further to maintain doxorubicin 
chemical stability, its therapeutic activity was increased [64].  
Cisplatin is an effective drug for treating a wide variety of cancers, but many tumors 
develop resistance to this drug, limiting its benefits for the patients [65]. Cisplatin, 
encapsulated in NPs with lysosomal pH-sensitive cores, have shown to be able to reduce 
the intestinal/mesentery tumors in treated mice [66].  
1.2.2. Administration of Peptides and Proteins 
The development of modern pharmaceuticals requires not only identification of new 
therapeutic mechanisms, but also safe and efficient ways for drug administration. For 
example, the importance of biotechnological drugs, especially protein drugs, has 
increased during the last few years, and is expected to increase further as a result of 
massive current efforts on human genomics and proteomics. If the history of use of the 
protein drugs is observed, first peptide drugs used were porcine or bovine insulin for 
diabetes, starting from 1930 [67]. With the advancement of molecular biology since 
1970s several therapeutic proteins have been developed and produced, such as Growth 
Factors (GFs), hormones, erythropoietin, colony stimulating factors, interferon, viral or 
bacterial proteins (as vaccines) and monoclonal antibodies [68]. Proteins and other types 
of biological macromolecules are, however, easily degradable both chemically and 
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enzymatically, and may also lose their biological activity through conformational 
changes and aggregation. In order to maintain the biological activity of such 
biotechnological drugs they must frequently be administered together with drug carriers. 
However, for several years, large molecules such as proteins were not considered 
feasible candidates for controlled release systems because they were considered too large 
to slowly diffuse through most polymeric materials. Nowadays, a number of studies have 
demonstrated that NPs can also enhance the oral bioavailability of encapsulated 
therapeutic peptides and proteins, such as insulin and GFs. Daily subcutaneous injections 
of insulin are tedious treatment for patients with insulin-dependent diabetes. Considering 
the number of patients affected by this disease, several efforts have been done to make 
insulin orally administrable [69]. NPs delivery systems may provide a solution for oral 
administration of insulin. In fact, it has been demonstrated that with the use of NPs is 
possible to allow the protection of insulin against the harmful gastric environment 
(chemical degradation), and prevent enzymatic degradation [70].  
GFs represent another important class of therapeutic proteins. GFs have strong tissue 
inductive properties, but their short half-life combined with high clearance rates have 
motivated the development of delivery systems capable of maintaining elevated 
concentrations to achieve therapeutic efficacy. A summary of NPs and other DDS loaded 
with GFs are reported in table 2 [71]. The market for synthetic therapeutic peptides rose 
from €5.3 billion in 2003 to €8 billion in 2005. It has been estimated that it will reach 
€11.5 billion in 2013. This excludes peptides, proteins and antibodies extracted from 
natural sources or produced by recombinant DNA technology, cell-free expression 
systems, transgenic animals and plants and enzyme technology [72].  
 
TABLE 2: Summary of in vitro investigations of NPs loaded with GFs 
Growth 
Factor   
NPs system Observations 
bFGF 
(FGF-2) 
PCL-PEG-PCL After an initial burst of ~60%, bFGF was released for 8 days with 70% of 
total bFGF release 
Tetronic®-PCL-
heparin micelle 
bFGF was released for over 2 months due to specific interaction with 
heparin 
Chitosan/dextran 
sulfate/PLL 
Nanocapsules were made by layer-by-layer method. bFGF activity was 
retained in the capsules 
Chitosan/ 
tripolyphosphate 
~70% of bFGF was released at 24 h. bFGF integrity was not affected by 
the encapsulation procedure 
Chapter I: Introduction 
18 
 
BMP-2 
PEI-coated BSA 
BMP-2 release was controlled by PEI coating concentrations. PEI 
coating reduced the initial burst release compared to the uncoated NPs. 
BMP-2 activity was retained 
PLL-coated BSA BMP-2 activity was retained 
Calcium phosphate 
NPs in PLGA 
microparticles  
A sustained release of BMP-2 for over 7 weeks in a reasonably linear 
profile 
Dextran Released BMP-2 stimulated proliferation and differentiation of rabbit 
bone marrow stem cells 
KGF-2 
(FGF-
10) 
Dextran 
sulfate/polycations 
≥80% of the encapsulated KGF-2 was released over 11 days for all 
formulations. The released protein enhanced the proliferation of EC, 
compared to free protein solution. 
EGF 
Polystyrene/Poly 
(methacrylic acid) 
EGF was released as a pseudo-zero order pattern after initial burst effect 
of 50% 
G5 PAMAM 
dendrimers 
The PAMAM-EGF conjugate stimulated cell growth to a greater degree 
than free EGF 
PEG-coated 
DPPC/CHO 
liposomes 
Enhanced EGF resistance to proteases, higher permeability of EGF 
across Caco-2 cells 
DPPC/LPC 
liposomes 
Increased osteoclast recruitment and enhanced teeth movement 
IGF-I PLGA Preparation methods affected the IGF-I release 
BMP-7 
Core/shell NPs 
composed of 
liposome (CHO and 
DDAB) /sodium 
alginate/chitosan 
Burst release was reduced by layer-bylayer coating of liposome, and up 
to >85% of BMP-7 was released over 4 weeks. The preosteoblast 
differentiation was enhanced. 
TGF-β3 Heparin/PLL Promote neocartilage formation after 4-week cultivation with MSCs  
VEGF 
Polycations/dextran 
sulfate 
75% of VEGF was released in a 10-day period for all NP formulations 
PLGA/Pluronic F-
127/heparin 
A linear, sustained release of VEGF without burst release was achieved 
for 37 days with 85% of the loaded VEGF being released 
Lecithin/F-127 Sustained released of VEGF was affected by the lecithin amount in the 
system 
 
1.2.3. Oligonucleotides and Plasmids 
The better understanding of the biological pathways involved in the development of 
several pathologies is leading to new therapeutic approaches aiming at eradicating these 
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diseases at the source. The DNA molecule has been one of the most important sources 
not only for the understanding of the fundamental basis of human life but also for the 
development of a novel group of therapeutics modeled on its endogenous structure. 
Although most of the DNA-based drugs are in early stages of clinical trials [73], this 
class of compounds has emerged in recent years to yield extremely promising candidates 
for a wide range of diseases, including cancer, AIDS, neurological disorders such as 
Parkinson’s disease and Alzheimer’s disease, and cardiovascular disorders [74]. 
Elucidation of the human genome has also provided a major impetus in identifying 
human genes implicated in diseases, which may lead to the development of DNA-based 
drugs for gene replacement or potential targets for gene ablation. In addition, using 
genomic data, potent DNA-based drugs may be developed for personalized medicine 
[75].  
DNA-based therapeutics include plasmids containing transgenes for gene therapy, 
oligonucleotides, ribozymes, DNAzymes, aptamers and small RNA, termed “short 
interfering RNAs” (siRNAs) [76]. RNA interference (RNAi) is a biological mechanism 
whereby the presence of double-stranded RNA (dsRNA) interferes with the expression 
of a particular gene that shares a homologous sequence with the dsRNA [77]. The RNAi 
machinery, ﬁrst discovered in plants, was later demonstrated in the roundworm 
Caenorhabditis elegans by delivery of dsRNA using a microinjection technique. The 
introduction of dsRNA molecules could produce the interfering activity and result in the 
highly speciﬁc inhibition of complementary gene expression in C. elegans [78]. Recent 
studies have provided insights into the molecular mechanisms of RNAi, in which dsRNA 
induces the silencing of homologous mRNA. In the cytoplasm of mammalian cells, an 
enzyme known as Dicer initiates RNA silencing by breakdown of long dsRNA to 
generate small interfering RNA (siRNA) of about 21–23 nucleotides in length. The 
resulting siRNAs are incorporated into an RNA-induced silencing complex (RISC) and 
unwound into a single-stranded RNA (ssRNA), which is followed by the degradation of 
sense strand ssRNA [79]. The concept of “gene silencing” is not unique to siRNA, but 
researchers have been silencing genes using single-stranded antisense 
oligodeoxyribonucleotides (ODNs) for decades. In the classical antisense strategy, the 
antisense strand of a DNA fragment corresponding to a target gene is delivered inside a 
cell where it binds complementarily with the sense strand of a target mRNA, producing a 
partially double-stranded ODN/mRNA complex degradated by endogenous cellular 
nucleases and preventing the recognition of the mRNA by ribosomes [80]. siRNA and 
plasmids DNA(pDNAs) are both double-stranded nucleic acids, have anionic 
phosphodiester backbones, same negative charge to nucleotide ratio, and can interact 
electrostatically with cationic agents. pDNAs are often several kilo base pairs long, 
possess a molecular topography which allows them to be condensed into small, 
nanometric particles when complexed with a cationic agent. pDNA, siRNA, and ODNs 
based therapies require the intracellular delivery of the active agent to the target cells. 
Concerning pDNA, it also requires the integration (in some cases) into the host cell 
genome and the subsequent expression of the resulting transgene. siRNA and ODNs 
have only to travel to the cytosol to reach the target mRNA [81]. The administration of 
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naked pDNA, siRNA and ODN is mainly limited by their short half-life in vivo, 
rendering them typical candidates for drug delivery technology applications [82].  
In the past, the use of genetically altered natural viruses as gene carriers had been 
investigated, but they showed safety and immunogenicity limitations, and high costs. 
Non-viral vectors, mainly based on cationic lipids and polymers, are the most 
investigated strategies.  
This cationic material can electrostatically interact with negatively charged DNA and 
generate self-assembled nanocarriers with several advantages such as scale manufacture, 
low immunogenic response, and the capacity to carry large inserts [83]. The most 
frequently studied cationic polymers include poly(ethylenimine) (pEI), poly(2-
dimethylaminoethyl methacrylate) (pDMAEMA), and poly-L-lysine (pLL). Generally, 
their transfection efficiency is lower than that of viral vectors, and to date, their systemic 
administration has resulted in a toxic response incompatible with clinical applications 
[84]. They are non-degradable, with consequent risk of accumulation in the body, most 
of them show cytotoxicity depending on their chemical structure and molecular weight, 
likely due to adverse interactions with cellular membranes [85]. The use of 
biodegradable carriers would limit the accumulation of macromolecular material and 
promote the release of the active agent into the cytosol, following the degradation of the 
system itself. Sufficiently long lifetime of the carrier is required to reach the target site 
after systemic administration, as well as degradation of the system, preferably upon a 
certain intracellular trigger (pH, redox potential, presence of enzymes), to release the 
DNA efficiently into the cell [86].  
1.3. Biomedical and Pharmaceutical Applications 
1.3.1. Angiogenesis  
Angiogenesis is the physiological and vital mechanism required for new blood vessels 
formation [87]. This complex process involves activation, migration and proliferation of 
endothelial cells from pre-existing vessels, beginning during embryogenesis and 
continuing throughout life in health and disease body, because is essential for tissue 
regeneration [88]. However, angiogenesis is also an essential step in pathologic 
processes, in which its spatial and temporal regulation is compromised. The excessive or 
inadequate angiogenesis leads to pathology conditions such as tumors and chronic 
inflammatory disorders [89].  
The study of angiogenesis is having a profound impact on the biological and medical 
world. The recorded history of vasculogenesis and vascular remodeling dates back to at 
least two centuries ago. In 1787, the British doctor John Hunter was the first to observe 
the growth of blood vessels. He suggested that the new vascularization is regulated by 
metabolic compounds both in health and disease [90]. During the 19th century, a lot of 
works were focused on micro-anatomical description of vascular beds and 
microcirculatory structure, in different organs and species. Also the concepts of vascular 
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regulations, in response to metabolic stimulation, started to be a new field of interest. 
The next major phase of attention to angiogenesis came in the late 20th century, in 
particular with the work of doctor Judah Folkman. In his work, he introduced the term 
angiogenesis and hypothesized that tumor growth is dependent upon angiogenesis. 
Finally, more than 30 years after his publication, angiogenesis is a focal point in cancer 
research and treatment of many diseases such as peripheral and myocardial ischemia, 
chronic wounds and healing of skin ulcers [91]. Nowadays, angiogenesis process is 
widely studied and understanding the mechanism of its regulation is a new challenge for 
the development of new therapies. Angiogenesis is a highly regulate process and is 
controlled by the net balance between many molecules that have positive and negative 
regulatory activity including GFs. GFs play a key role in maintaining angiogenesis 
balance, because when they are produced in excess in comparison to the angiogenetic 
inhibitors, the balance is tipped in favor of blood vessel growth [92]. When inhibitors are 
present in excess, angiogenesis is stopped. The normal, healthy body maintains a perfect 
balance of angiogenesis modulators and when this balance is compromised the body 
undergoes to pathological conditions [93].  
Angiogenesis may be divided into four stages: (I) activation of the endothelial cells that 
leads to a localized degradation of the basal membrane of the parent vessel and of the 
extra-cellular surrounding matrix; (II) oriented migration of endothelial cells in the 
extracellular matrix; (III) proliferation of endothelial cells; (IV) differentiation of these 
cells with organization into tubular structures with a new basal lamina. Through these 
stages the new capillaries form a new vascular network (Figure 6) [94].   
 
 
Figure 6: Schematic representation of angiogenesis process (modify from [95]). 
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1.3.2. Mechanisms of Angiogenesis Regulation 
Blood vessels are part of the circulatory system that transports blood throughout the 
body. There are several types of blood vessels including arteries, veins and capillaries 
[96]. These blood vessels have a common internal structure. The outer layers are 
connective tissue and contain the nerves that control the muscles. The next inner layers 
are elastic fiber and connective tissue containing vascular smooth muscle. These muscles 
control the diameter of the blood vessel and allows the blood vessel to expand and 
contract, controlling the amount of blood flow and blood pressure [97]. The inner most 
layer consists of endothelial cells surrounded by a basement membrane [98]. The 
endothelial cells are among the most quiescent and genetically stable cells of the body 
and they are in direct contact with the blood [99]. During angiogenesis, endothelial cells 
can proliferate rapidly, being one of the main events that are required for the formation 
of new capillary blood vessel. Vascular endothelial cell proliferation is associated with 
degradation of basement membrane, which leads to sprouting of pre-existing micro 
vessels [100]. These vessels invade the extra cellular matrix, form tubes and finally the 
tips of the tubes connect to create loops that are capable of conducting the blood flow 
[101]. The molecular mechanisms responsible for angiogenesis are extraordinarily 
complex: multiple genes must coordinately express their products in appropriate 
amounts and in an appropriate time-dependent manner. Table 3 lists some GFs and 
cytokines that have been recognized to be involved in the process of angiogenesis [102]; 
[103];[104]. Some major GFs and their receptors will be introduced in detail in the 
following paragraph.  
 
 
 
TABLE 3: Growth factors and cytokines involved in angiogenesis process  
Angiogenic Growth Factors and Cytokines  Abbreviation   
Acidic fibroblast growth factor  aFGF   
Angiopoietin  Ang   
Basic fibroblast growth factor  bFGF   
Heparin-binding epidermal growth factor  HB-EGF   
Insulinlike growth factor  IGF   
Placental growth factor  PLGF   
Platelet-derived growth factor  PDGF   
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Vascular endothelial growth factor  VEGF   
Hepatocyte growth factor  HGF   
Transforming growth factor-beta  TGF-β   
Granulocyte macrophage colony-stimulating factor  GM-CSF   
Monocyte chemoattractant protein-1  MCP-1   
Interleukin 8  IL-8   
Interleukin 20  IL-20   
Leptin  LP  
Platelet-derived endothelial cell growth factor  PD-ECGF  
Pleiotrophin  PTN  
Progranulin  PGRN  
Tumor necrosis factor-alpha  TNF-α  
Follistatin FST  
 
1.3.2.1. Growth Factors 
Growth factor is a term used to describe a broad range of structurally different molecular 
families and individual proteins best known for their ability to enhance cell proliferation 
and growth. They have an array of putative functions during the development including 
regulating tissue morphogenesis, angiogenesis and cell differentiation. They also play an 
important role in the maintenance of tissue homeostasis and wound healing in the adult. 
Their activities are mediated via binding to transmembrane receptors that often contain 
cytoplasmic tyrosine kinase domains [105]. Some of the most important GFs that work 
in the angiogenic process, such as PDGF, VEGF and FGF, have been identified in 
platelets. 
PDGF was discovered more than two decades ago and is the major mitogens for many 
cell types of mesenchymal origin (e.g. fibroblasts and smooth muscle cells). Nowadays, 
five different isoforms, generated by alternative splicing are known PDGF-AA, PDGF-
BB, PDGF-AB, PDGF-CC and PDGF-DD [106]. All PDGF are small proteins with 
molecular weight in the range of 28-30 kDa, and all isoforms have a common structure 
characterized by the typical growth factor domain involved in the dimerization of the 
two subunits, and in receptor binding and activation [107]. PDGF receptors (PDGFRs) 
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consist of - α and -β subtype, both of which are belonged to tyrosine kinase receptors 
(RTKs). Interactions between PDGF and PDGFRs are complex, for example, PDGFR-α 
is activated by PDGF-AA, AB, BB and CC, and PDGFR-β is activated by PDGF-BB 
and DD. On the other hand, the heterodimer PDGFR-αβ can be activated by PDGF-AB, 
BB and with low affinity with PDGF-CC and DD. In general, PDGF-A and C are mainly 
expressed by neuronal, epithelial and muscle cells. PDGF-B is more related to 
megakaryocytes, endothelial cells and neurons. Binding of PDGFs to PDGFRs leads to 
receptor dimerization and establishes the docking sites for various signaling molecules 
which are responsible to create a signaling network that initiates multiple cellular 
responses. These cascade activations of different signal molecules lead to cell growth, 
cell migration and antiapoptosis [108]. PDGFR- α and β mediates different biological 
events. PDGFR-α signaling is mainly important in gastrulation and development of lung, 
intestine, central nervous system and skeleton. Correspondingly, the β receptor initiates 
signaling primarily involved in the blood vessel system and hematopoiesis, but leads to 
similar mitogenic and migration effects [109]. All isoforms of PDGF stimulate 
angiogenesis, in particular PDGF-BB. The mechanisms of angiogenesis regulation by 
PDGF-BB are complex and involve a multi steps signaling. After the binding to its 
receptor on vascular endothelial cells, PDGF-BB activates the intracellular signal 
transduction pathways for the endothelial cells proliferation and migration. These 
processes lead to vascular tube formation and the recruitment of smooth muscle cells that 
initiate the stabilization of new blood vessels [110]. PDGF-BB also increases the 
expression of several angiogenic factors that include increased VEGF expression in 
fibroblasts and endothelial cells [111].  
In 1983 the VEGF was first identified as a protein able to induce angiogenesis and 
currently it is one of the most studied growth factor [112]. The VEGF family includes 
six glycoproteins derived from an alternative splicing of the single gene consisting of 
eight exons. These isoforms differ for their amino acid length and, most importantly, for 
their ability to bind cellular heparan sulfates. This binding is critical to the VEGF 
biology because the loss of heparin binding results in a substantial loss of mitogenic 
activity of VEGF [113]. All VEGF ligands mediate their angiogenic effect via the RTKs, 
such as VEGFR-1, VEGFR-2 and VEGFR-3. When VEGF binds the extracellular 
domain of their receptor, a cascade of downstream proteins is activated after the 
dimerization and autophosphorylation of the intracellular RTKs. The VEGF receptors 
have an extracellular portion consisting of 7 immunoglobulin-like domains, a single 
transmembrane spanning region, and an intracellular portion containing a split tyrosine-
kinase domain [114]. Within this family, the most relevant isoforms are represented by 
VEGF-A, VEGF-C and VEGF-D. VEGF-A has been regarded as the major player for 
angiogenesis and it binds to VEGFR-1 and VEGFR-2, of which VEGFR-2 is the major 
mediator of the mitogenic and angiogenic effects of VEGF-A [115]. However, the 
precise role of the VEGFR-1 receptor in angiogenesis remains elusive. VEGF-C and 
VEGF-D activate VEGFR-3 receptor, essential for lymphatic endothelial cell growth, 
migration and survival [116]. The importance of VEGF family and their receptors 
emerge from their lack or deletion during the development stages. Indeed loss of a single 
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VEGF allele in mouse models leads to the developmental deformities in the forming 
vasculature and embryonic death between days 11 and 12. Moreover, mice lacking either 
VEGFR-1 or VEGFR-2 even die earlier, between embryonic days 8.5 and 9.5 [117].  
Another important set of proteins that mediates angiogenesis is FGFs family. FGFs are 
soluble GFs which have both acidic (aFGF) and basic (bFGF) variety. To date, more 
than twenty distinct FGFs have been discovered, numbered consecutively from 1 to 23 
[118]. Indeed, FGF-23 has been identified as the last member of FGFs family and it is 
involved in the regulation of phosphate metabolism [119]. FGFs have a molecular 
weight range from 17 to 34 kDa, and most of isoforms, are characterized by an internal 
core region of similarity with 28 highly conserved amino-acid residues important for the 
receptor binding [120]. FGFs mediate their signals through four structurally related 
RTKs on cell surface (FGFR-1, 2, 3 and 4) to induce numerous biological effects such as 
mitogenic, chemotactic and angiogenic activity in cells of mesodermal and 
neuroectodermal origin [121]. Nevertheless, one of the best-characterized functions of 
FGFs is the induction of new blood vessels, and together with the VEGF, FGFs are the 
most important regulators of these processes. bFGF may contribute in angiogenesis in 
two primary ways: by modulating endothelial cell activity and by regulating VEGF 
expression. In brief, in one way, bFGF is involved in the proteolytic digestion of 
extracellular matrix by invading endothelial cells; a second way is by inducing 
expression of VEGF in which has been found to be dependent on bFGF dose [122]; 
[123]. 
Like PDGF and VEGF, bFGF binds with high affinity with glycosaminoglycans, in 
particular with heparin (Hp) [124]. Hp is a linear mucopolysaccharide composed of 
alternating units of sulfated d-glucosamine and d-glucuronic acid and this esterified 
sulfuric acid component gives to Hp its acidic property and electronegative charge [125]. 
Furthermore, Hp is a naturally occurring anticoagulant synthesized and secreted 
primarily by the mast cells in the body. Hp assumes an important biological function due 
to its capacity to bind different molecules, including extracellular matrix proteins, 
enzymes, and protease inhibitors.  
In recent years, a large interest comes from the capability of the Hp to bind several GFs 
and cytokines involved in the angiogenesis process, thus affecting their biological 
activity [126]. The negative charges of Hp, provided by sulfo and carboxyl groups, are 
involved in the interactions between Hp and proteins. In fact, the proteins able to interact 
with Hp are characterized by the presence of clusters of positively charged basic amino 
acids that form ion pairs with spatially defined negatively charged sulfo or carboxyl 
groups of the Hp, and this particular region is called heparin-binding domain [127]. A 
number of studies have been undertaken to determine whether there is a consensus 
sequence of basic amino acids arranged in a specific way in heparin-binding domain. 
Instead, two consensus sequences of amino acids have been found: XBBXBX and 
XBBBXXBX where B is a basic residue and X is a hydropathic residue [128]. The 
interaction between Hp and proteins, such as angiogenesis related GFs, is also important 
to potentiate their biological activities. Indeed, several investigations have demonstrated 
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that when GFs interact with Hp, their bioavailability is improved. This is due to Hp that 
allows the localization of GFs at the cell surface or in the extracellular matrix and 
promotes the interaction between GFs and their respective receptors. In addition, the 
interaction of Hp with GFs has been shown to protect them from heat and acid 
inactivation and from enzymatic degradation [129, 130].    
1.3.3. Therapeutic Angiogenesis 
The term therapeutic angiogenesis was first introduced to describe the stimulation of 
neovascularization in order to treat or prevent pathological clinical situations 
characterized by local hypovascularity [131]. Traditionally, therapeutic angiogenesis has 
been achieved by surgical methods (i.e. the transposition of autologous tissues with 
uncompromised vasculature). However, a significant number of patients have still shown 
clinical situation characterized by severe general ischemic conditions, which make these 
symptomatic patients not suitable for the traditional surgery treatments. Nowadays, the 
advances in nanotechnology field may add a new clinical tool to achieve therapeutic 
angiogenesis by pharmaceutical route, such as the administration of GFs as alternative 
treatment for these diseases [132].  
1.3.3.1. Peripheral Arterial Disease  
Peripheral arterial disease (PAD) is referred to the obstruction of large arteries in the 
arms or legs, is a pandemic condition that lead to an insufficient tissue perfusion and has 
the potential to cause loss of limb or even, in severe cases, loss of life [133]. Smoking, 
high cholesterol, diabetics and high blood pressure are also significant risk factors for 
PAD. Moreover PAD can result from atherosclerosis, inflammatory processes leading to 
stenosis, an embolism, or thrombus formation [134]. The incidence of PAD in Europe 
reaches 1% per annum over the age of 65 years and 30% of deaths worldwide are 
attributed to PAD. In the United States 1.4 million suffer from this pathology with an 
estimated 350876 new cases diagnosed each year [135]. However, in settings such as 
acute limb ischemia, this pandemic disease can be life threatening and can require 
emergency intervention to minimize mortality [136]. The common treatments for PAD 
are represented by surgical revascularization and angioplasty, but limb amputations are 
still performed for the treatment of severe cases [137]. Although surgical and 
endovascular techniques give good initial results for symptomatic PAD, the progressive 
nature of atherosclerosis and bypass grafts commonly lead to patients re-presenting with 
worsening claudication or critical limb ischemia (CLI), such as a more severe form of 
PAD and principal cause of lower limb amputations [138, 139]. No effective 
pharmacological measures are available for this situation and in many cases the only 
option is limb amputation. In order to achieve limb salvage and in view of the poor 
results with current therapies, much interest has been shown in developing alternative 
treatment within therapeutic angiogenesis such as gene therapy, cell therapy and the use 
of drug delivery systems [140]. Gene therapy involves the insertion of genetic material, 
plasmid or viral vector, into dysfunctional cells or tissues by intramuscular or intra-
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arterial injection. The target of gene therapy is aimed to induce locally expression of the 
GFs naturally involved in the process of vascular growth and repair. The most 
commonly GFs used for gene therapy are VEGF and FGF [141]. Various isoforms of 
VEGF have been delivered to patients in clinical studies and the isoform VEGF-A165 
was first tested in humans in 1996 following several successful preclinical trials with 
animal ischaemic hindlimb models [142]. Concerning the use of FGF, the isoforms FGF-
1 and FGF-2 have been studied most in gene therapy for PAD. FGF-1 plays a key role in 
new vessel development and is widely used for gene therapy. In particular clinical trials 
have demonstrated that in patients treated with injections of FGF-1 the amputation rate 
has been decreased from 55% to 37% [143]. Gene therapy based on injection of FGF-2, 
using a nonviral gene transfer approaches, demonstrated to significantly increase the 
blood flow and angiogenesis in a rat model of hindlimb ischemia [144]. As alternative 
strategy to conventional treatment for PAD, in recent years, there has been an increased 
interest also in cell therapy. The use of stem cell as an agent to induce new 
revascularization emerged in 1997 with the discovery, in adult human peripheral blood, 
of the circulating endothelial progenitor cells (EPCs) and their ability to successfully 
promote vascularization in ischemic tissues [145]. Current investigations in regenerative 
medicine are evaluating the potential of stem/progenitor cells, such as bone marrow 
derived stem cells, from a variety of non-hematogenous sources, tissue-resident stem 
cells, and pluripotent stem cells [146]. The therapeutic application of bone marrow 
mononuclear cells has confirmed that these cells support collateral vessel formation in 
animal models [147]. The clinical trials for the use of bone marrow mononuclear cells, 
administrated in patients by intramuscular injection, have demonstrated the improvement 
of blood perfusion in ischemic limbs and reduction of amputation rates [148]; [149]; 
[150]. Nowadays, many studies are in progress to improve the integration and survival of 
the transplanted cells in order to obtain new cell therapies for the treatment of PAD 
[151].  
The increase of interest in the field of nanotechnology, to overcome the problems related 
with gene and cell therapy, involved the use of NPs for the delivery of pro-angiogenic 
compounds in the treatment of PAD. The most studied NPs carrier are represented by 
those used for the delivery of angiogenesis related GFs, even if in recent years also 
nucleic acid, such as RNAs are under development [152]. To date, NPs loaded with 
bFGF and VEGF respectively have been developed. The bFGF loaded NPs have shown 
the capacity to induce capillary growths in a hind-limb ischemia mouse model, treated 
for 4 weeks of subcutaneous injection of bFGF NPs [153]. Regarding the use of VEGF 
loaded NPs it has been demonstrated that injection in mice' ischemic limbs induces the 
growth of new blood vessels [154]. Several other NPs for GFs delivery have been 
developed, including IGF-1 and TGF-β3 loaded NPs [155]. 
1.3.3.2. Chronic Wounds 
Chronic wounds occur when a wound does not heal in an orderly set of stages. If within 
three months, a wound is not heal is often considered chronic. In acute wounds, there is a 
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precise balance between production and degradation of molecules, such as collagen, 
necessary for normal healing. In chronic wounds this balance is lost and, the phase of 
degradation plays the main role, and consequently healing of chronic wound may never 
occur (Figure 7). In today’s society, chronic wounds represent a major health care 
burden. It has been estimated that 15% of individuals with diabetes mellitus will develop 
lower extremity ulcers and 14–24% of diabetic patients with foot ulcers will eventually 
undergo amputation. Approximately 100000 limb amputations are performed in diabetic 
patients each year in the United States [156]. Understanding causes of chronic wound is 
not easy, because vary from patient to patient, and are related with particular patient’s 
conditions, such as poor blood circulation, diabetes or can develop in nursing home 
patients who are confined to bed. These wounds cause in patients an acute pain, physical 
stress, and in the severe cases may result in a serious infection, gangrene, and may even 
require amputation [157]. There are three main types of chronic wounds: venous ulcers, 
diabetic ulcers, and pressure ulcers [158]. Venous ulcers usually occur in the legs, 
account for the majority of chronic wounds, and mostly affect the elderly. They are 
caused by improper function of tiny valves in the veins that normally prevent blood from 
flowing backward. The dysfunction of these valves impedes the normal circulation of 
blood in the legs, causing tissue damage and impaired wound healing [159]. Diabetic 
patients are particularly susceptible to developing ulcers. People with advanced diabetes 
have a diminished perception of pain in the extremities due to nerve damage. Diabetes 
also impairs the immune system and damages capillaries [160]. The major causes of foot 
ulcers in diabetic patient can be attributed to neuropathy, mechanical stresses and 
ischemia [161]. Pressure ulcers typically occur in people who are bedridden or whose 
mobility is severely limited. Pressure ulcers are caused by a loss of blood circulation that 
occurs when pressure on the tissue is greater than the pressure in capillaries, thereby 
blood flow to the tissue is completely or partially obstructed [162].  
The conventional treatments for chronic wounds often are based on topical therapies 
with antibiotics or anti-inflammatory drugs but with limited success. Currently, other 
therapies are under investigations and involve the use of GFs. The use of GFs could be 
one of the best strategies for the treatment of these pathological conditions because 
defects in angiogenesis are always present in chronic wounds, and GFs based therapies 
have shown to promote angiogenesis and accelerate healing [163]. These novel strategies 
to treat chronic wounds are based on synthetic medical devices that mimic the natural 
healing process and also provide options for controlled GFs or cell delivery. To 
specifically address GFs to the target site, recent approaches have focused on the 
incorporation of GFs within platelet gels (PG) or within polymer based NPs [164]. PG 
provides, in situ, exogenous additional GFs that can accelerate tissue reparation and 
regeneration [165]. In a study on a 57-year-old man with type 2 diabetes and a wound of 
six months duration, the treatment with PG lead to the complete closure of the ulcer by 
the fourth week [166]. Due to their low stability, the administration of GFs generally 
requires a vector, and the recent expansion in the field of nanotechnology is offering a 
wide variety of opportunities in this field. Recently, NPs have attracted much attention 
due to their unique properties: reduce GFs side-effects, provide an extended availability 
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of GFs at the local environment, and protect them against degradation by proteolytic 
enzymes [167].  
Gene therapy and stem cell research have become areas of interest for developing new 
strategies for wound healing, but still remain challenges in the selection of optimal cells 
targeting, development of sequential therapeutic methods, and identification of factors 
which may be detrimental to the introduction of genes. Further research is needed on the 
intrinsic molecular mechanisms that keep stem cells pluripotent or direct them along 
particular differentiation pathways [168].   
 
     
 
Figure 7: Schematic representation of processes involved in wound healing (modified from 
[169]). 
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1.3.3.3. Ischemic Heart Disease 
Ischemic heart disease (IHD), also called coronary artery disease (CAD), is a condition 
that affects the supply of blood to the heart. The coronary arteries are the only existent 
blood supply to the heart muscle [139]. In a pathological situation, a blockage in the 
coronary arteries reduces suddenly the supply of blood in a portion of the heart muscle, 
and consequently leads to the death of that area, resulting in a heart attack. In the 
pathophysiology of IHD, two processes are involved: supply and demand of myocardial 
oxygen. Myocardial ischemia occurs when there is imbalance between supply and 
demand for oxygen. In fact, in some conditions, the impairment of oxygen is secondary 
to decreased blood flow and is the main responsible for myocardial ischemia [170]. The 
major risk factors of the incidence of IHD could be smoking, diabetes mellitus, high 
cholesterol levels, hypertension, stress and genetic predisposition factors [171]. IHD is 
the most common cause of morbidity and mortality in the Western countries [172]. 
There have been enormous advances in surgical methods for the treatment of IHD, such 
as angioplasty, coronary artery bypass graft and revascularization by percutaneous 
coronary intervention [173]. However, surgical technologies are not suitable for all 
people suffering from IHD. Many patients are not optimal candidates for surgical 
treatment because of co-morbid diseases, unsuitable anatomy, or the risks of the 
procedure [174]. Thus, is an important challenge finding additional or alternative 
treatments for IHD. Nowadays, the progresses in therapeutic angiogenesis offer the basis 
for the development of new therapies through the use of pro-angiogenic GFs. Controlled 
released systems, such as NPs, offer a potent tool for the administration of GFs. The 
sustained release of GFs may be necessary for the maintenance of stable 
revascularization and thus increase treatment efficacy with a lower dose of GFs. Indeed, 
the therapeutic angiogenesis approach is supported by a preclinical evidence showing 
improvements in blood flow, revascularization and myocardial function after angiogenic 
GFs delivery in different animal models of myocardial disease [175]. Moreover, the use 
of NPs, make it a targeted approach for the treatment of IHD. Targeted NPs may be 
injected intravenously, circulate in the body for long periods, and bind to desired tissues. 
In the infarcted heart NPs have been used to target macrophages and blood vessels [176].  
Other new strategies, such as gene and stem cells therapies, are also currently under 
investigation as an alternative approach for the treatment of IHD. Nevertheless, even if 
the clinical trials are promising, gene and stem cells therapies need to be better 
understood. Several obstacles have contributed to their limited effectiveness, such as 
problems with viral vectors and immune responses as regards the gene therapy, and 
isolation, identification and in vivo expansion for stem cells therapy [177]; [178].   
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1.4. Platelet Rich Plasma 
1.4.1. Platelets 
Platelets are small discoid blood cells (1-3 µm) and are only about 20% of the diameter 
of red blood cells [179]. The average platelet count ranges from 1.5 to 3.0 x 10-5 ml of 
circulating blood, and the in vivo half-life time of platelets is about 7 days. Platelets are 
synthesized in the bone marrow, the same as the red cells and most of the white blood 
cells [180]. Platelets are produced from very large bone marrow cells called 
megakaryocytes by pinching off pieces of cytoplasm and extruded into the circulation. 
As megakaryocytes develop into giant cells, they undergo a process of fragmentation 
that results in the release of over 1,000 platelets per megakaryocyte [181]. Platelets are 
actually not true cells but merely circulating fragments of cells, but they contain many 
structures that are critical to stop bleeding. Platelets contain proteins similar to muscle 
proteins, a ring of contractile microtubules (cytoskeleton) around their periphery 
containing actin and myosin, which allow them to change shape and become active 
[182]. Platelets activation occur when they are stimulated by a break in the blood vessel 
wall. The platelets change their shape, become round and extend long filaments 
(pseudopods), that allow to make contact with the broken vessel wall or with other 
platelets, and in this way they are able to form a plug to seal the broken blood vessel 
[183]. Normally, in the resting state, platelets are nonthrombogenic and require a trigger 
before they become a potent and an active player in hemostasis and wound healing. 
Inside the platelet, a number of intracellular structures are present containing glycogen, 
lysosomes, and two types of granules known as dense granules and α-granules able to 
secrete other proteins [184]. Dense granules are 3-8 granules per platelet, are small 
(~150 nm) and appear as dense bodies due to their high calcium and phosphate contents. 
In addiction dense granules contain adenine nucleotides and serotonin and P-selectin. 
During platelets activation, the membrane of these granules interacts with the platelet 
plasma membrane and they merge together. This event allows the subsequent release of 
granule’s content into the extracellular environment. The released constituents contribute 
to recruit other platelets (aggregation) and also contribute to local vasoconstriction [185]. 
The importance of the dense granules into the normal hemostasis is shown in two rare 
human pathological conditions, such as Hermansky-Pudlak syndrome and Chediak-
Higashi syndrome, in which the deficiency of these granules is associated with 
predisposition to bleeding [186]; [187]. Alpha-granules are the largest platelet granules 
(~200-400 nm), are 50-60 per platelet and are responsible of the granular aspect of the 
platelets’ cytoplasm. In the α-granules are present the majority of platelet factors 
involved in hemostasis, inflammatory process and wound healing (table 4) [188]. 
Further, α-granules demonstrate heterogeneity in their constituents and specific sub-
populations, probably due to the fundamental role that alpha-granules play in platelets 
aggregation, thrombosis and regulation of cell proliferation via release of various GFs. 
During platelets activation the alpha-granules release occurs with an intricate process 
because platelets contain complex machinery for granule release in which play an 
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essential role proteins receptor and membrane lipids [189]. The process involving 
coalescence in the platelet center, formation of a fusion pore that represents the initial 
site of mixing of two membranes and this fusion pore undergoes to rapidly expand until 
completely fusion of granule membrane with platelet membrane and consequent release 
of granule contents [190].  
 
TABLE 4: Alpha-granule contents in human platelets 
Platelets alpha-granules contents   
Adhesion molecules Platelet Endothelial Cell Adhesion Molecule-1 (PECAM- 1/CD31) 
Fibrinogen 
von Willebrand Factor (vWF) 
Thrombospondin-1 (TSP1) 
Vitronectin, Fibronectin 
Mitogenic factors Platelet-derived Growth Factor (PDGF) 
Vascular Endothelial Growth Factor (VEGF) 
Transforming Growth Factor-β (TGF-β) 
Membrane proteins P- selectin 
CD40L 
Glycoprotein IIb/IIIa (GPIIb/IIIa, aIIbβ3 integrin, CD41/CD61) 
Coagulation factors Fibrinogen, Plasminogen, Protein S, Kininogens 
Factors V, VII, XI, XIII 
Protease inhibitors C1 inhibitor 
Plasminogen activator inhibitor-1 (PAI-1) 
Tissue factor pathway inhibitor (TFPI) 
Leucocyte recruitment Chemokines: PF4, RANTES, β- thromboglobulin, ENA-78, SDF - 1α 
 
1.4.2. Preparation of Platelet Rich Plasma 
Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets. It is 
prepared from a unit of autologous whole blood by means of extracorporeal blood 
processing techniques [191]. The blood is collected in the presence of an anticoagulant 
and centrifuged. An initial centrifugation at low speed separates the blood into three 
layers as a function of density: the top plasma layer, the middle layer (consisting of 
white blood cells and platelets), and the bottom layer (consisting of red blood cells). The 
top and middle layers are then centrifuged at high speed to separate Platelet Poor Plasma 
(PPP) and PRP (Figure 8). The volume of PRP collected is approximately 10% of the 
total blood used. Before application, PRP must be activated to release the GFs from the 
alpha-granules of the platelets [179]. The most common method of platelet activation for 
clinical use is to add calcium chloride/thrombin and store the PRP for 8 h at room 
temperature [192]. Other platelet activation methods include freeze/thaw, or addiction of 
trigger molecules, such as collagen and adenosine diphosphate (ADP). The choice of the 
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platelet activator would affect the timing and level of GFs release. Furthermore, the 
higher concentration of platelets in PRP would result in a greater level of GFs release. 
Other factors may influence the efficacy of PRP are centrifugation protocols, choice of 
anticoagulant, platelet integrity, and the presence of other cell types [193]. 
 
 
Figure 8: Technology of PRP preparation [194]. 
 
1.4.3. Use of Platelet Rich Plasma in Animal and Clinical Studies 
PRP has been clinically used in humans since the 1970s for its healing properties 
attributed to the presence of autologous GFs and secretory proteins that may enhance the 
healing process [195]. PRP is made from the patient’s own plasma and hence is 
completely safe, relatively inexpensive, and expected to release the right mixture of GFs 
for therapeutic use. In humans, PRP has been investigated and used as clinical tool for 
several types of medical treatments, including nerve injury, tendinitis, osteoarthritis, 
cardiac muscle injury, bone repair and regeneration, plastic surgery, and oral surgery 
[196]. PRP has also received attention in the popular media as a result of its use in 
treating sports injuries in professional athletes [197]. A number of studies have examined 
the effects of PRP on tissue regeneration and healing. Different studies, in diverse animal 
models, have demonstrated the capability of the PRP to promote and accelerate healing. 
A recent study on a rabbit model has indicated that after 4 and 12 weeks, the animals 
treated with PRP have shown an improved of the cartilage and bone formation [198]. 
PRP has also been demonstrated to improve the healing of acute traumatic wounds. 
Studies performed in a rat Achilles tendon rupture model and in equine with tendons 
rupture also demonstrated the efficacy of PRP to promote the healing. In particular, the 
study carried out in the rat model has shown an increase of the tendon strength and 
stiffness by 30% after 1 week [199]; [200]; [201].  
Clinical use of PRP has been also investigated in human subjects. However, the data 
regarding the efficacy of PRP in human are more limited. This is because of the data are 
not related only to the use of PRP, but to all autologous platelet concentrate, such as 
platelet gel and fibrin glue. Moreover, human studies are difficult to describe because 
reported cases may not have controls, have small sample sizes, and do not have a 
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standardized preparation of PRP. The available studies suggested that the use of PRP in 
human, promote wound healing and also could lead to decrease of the post-operative 
infections, pain, and blood loss. There have been publications on the use of PRP for 
several clinical applications, including periodontal and oral surgery, maxillofacial 
surgery, heart bypass surgery, and treatment of chronic skin ulcers [202]; [203]; [204]; 
[205]. As such, wound healing enhancement by PRP exists, however, a small collection 
of clinical studies have demonstrated a significant enhancement of hard- and soft-tissue 
healing with the use of PRP. In plastic surgery, the use of PRP has been largely limited 
to fibrin glues, primarily used to obtain hemostasis and adherence of skin flaps. In fact, a 
diverse use of fibrin glue for closure of surgery incisions, such as in face and neck lifts 
and breast reductions and augmentations, resulted in numerous advantages. These 
included the elimination of the need for drains, a reduction in post-operative pain and 
swelling, and improved wound healing [206]. In wounds treated with PRP, faster ulcers 
reepithelialized has been observed in patients treated with PRP, compared with patients 
with similar wounds, treated with placebo [207]. Moreover, PRP has been useful for the 
treatment not only of chronic wounds, but also in acute trauma wounds [208]. Treatment 
with PRP holds great promise. PRP does appear to be effective in the treatment of 
chronic injuries in wide medical fields.  
1.4.4. Platelet Lysate 
Platelets Lysate (PL) can be defined as a platelet derivate, obtained by platelets 
collection from blood samples, in which the presence of GFs and cytokines can promote 
tissue regeneration and cell proliferation [209]. There is increasing interest in the use of 
PL as a therapeutic biological product in the field of regenerative medicine as well as for 
various applications in cell cultures and cell therapy as a replacement of FBS (Fetal 
Bovine Serum). Currently, the major therapeutic applications of PL are to stimulate bone 
regeneration in oral, maxillofacial, plastic and orthopaedic surgery, or to accelerate 
wound healing of soft tissues, in particular in the treatment of ischemic leg ulcers [210]; 
[211]; [212]. For such clinical applications, PL obtained from an autologous single-
donor, is used as a topical product, as such or after activation by exogenous thrombin to 
induce the release and temporary entrapment of the GFs into a ﬁbrin rich biomaterial 
[164].  
FSB is the most widely used serum for animal cell culture, mainly due to its high 
concentration of GFs and low concentration of immunoglobulins. However, there are 
several problems with the use of serum such as availability, cost, unknown composition, 
variations between batches and complications of the purification of products [213]. In 
the last decade research has focused on alternatives to serum based media to overcome 
problems associated with the use of serum. In the 1970s it was demonstrated that platelet 
components promoted cell growth in vitro [214]. Based on this knowledge, PL has been 
studied as an alternative source for supplementation of cell culture medium. In fact, the 
use of PL containing multiple GFs has been proven by a number of researches to be 
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superior to FSB or other serum preparations, in terms of costs and proliferation rate, as 
regarding mesenchymal stem cells (MSCs) [215]; [216]; [217].  
PL can be obtained from PRP. The general procedure is to separate platelet fractions 
from the plasma by centrifugation steps and concentrate to a density of at least 1x10-9 
platelets/ml. Platelets can be activated with thrombin or lysed by repeated freeze-thaw 
cycles. Both mechanisms result in the release of GFs and mitogens that are stored in the 
platelets [218].   
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I. AIM OF THE WORK 
The research work carried out in the present PhD thesis is part of a long-standing 
research activity regarding the design and synthesis of polymeric materials for 
applications in Pharmaceutical and in Regenerative Medicine. This activity is ongoing in 
a research group comprising chemists, biologists, pharmaceutical technologists and 
engineers at the Laboratory of Polymeric Materials for Biomedical and Environmental 
Applications (BIOLab) of the Department of Chemistry and Industrial Chemistry of the 
University of Pisa.  
Controlled drug delivery technology represents one of the most rapidly advancing areas 
of science in which several fields, such as chemistry, pharmaceutical technology, and 
medicine are contributing to human health care. For many years, fundamental and 
applied investigations have focused on the development of pharmaceutical formulates 
allowing for maximization of the therapeutic efficacy and minimization of the adverse 
effects of the drugs of interest. 
The research project that constitutes the body of the present thesis involves 
multidisciplinary skills. The focal point consists in the realization of biocompatible 
polymeric nanoparticles (NPs) designed for the targeted release of proteins, in particular 
Growth Factors (GFs). The study has been undertaken within the framework of the 
research project funded by the Tuscany Region: “Biosurgery – Nanostructured materials 
based on fibrin and platelet factors able to promote angiogenesis”. The six months stage 
at the Laboratory of Microbiology, School of Life Sciences, Tsinghua University 
(Beijing, China), was part of the project funded by the European Community, entitled 
“Hyaluronan-based injectable material for tissue engineering” (Hyanji scaffold).  
The main goal of the research project is to produce GFs loaded NPs in order to obtain 
nanocarriers for the administration of these proteins in the treatment of ischemic 
diseases. Ischemic diseases remain among the most prominent health problems in the 
western countries. Defects in blood supply compromise tissues and organs functions 
causing several pathologic conditions, such as ischemic limbs and chronic ulcers. 
Therapeutic angiogenesis is a promising strategy for the treatment of these diseases. It is 
based on the utilization of angiogenic related GFs to enhance the natural healing 
processes in ischemic tissues. Two recombinant GFs, Vascular Endothelial Growth 
Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) were selected for the 
preparations of NPs. Moreover, since it is known that platelets are a great natural source 
of angiogenic related GFs, the possibility to encapsulate Platelet Lysate (PL), as natural 
source of GFs was investigated.  
In these research activities two polymers, with different characteristics (biodegradable 
and bioerodible) were employed. Poly (lactic-co-glycolic acid) [PLGA] and Poly 
(methacryloylglycylglycine-OH-co-hydroxypropylmethacrylamide) [Poly (Gly-co-
HPMA)] are polymeric matrices selected to carry out this project, in order to obtain 
nanosystems that allow respectively a fast (e.g. few days) and a slow (e.g. several weeks) 
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drug release. Moreover, a proteic model drug, Human Serum Albumin (HSA) was 
encapsulated with the intention of giving a better understanding of the suitability and 
versatility of the methods for the encapsulation of proteic drugs. In order to improve the 
maintenance of bioactivity of the encapsulated GFs, Heparin sodium salt (Hp) was used 
as stabilizing agent in all of the NPs formulations. NPs morphology, size, surface charge 
and encapsulation efficiency were determined, as well as the evaluation of drug release 
profiles. In the perspective of a practical application in the pharmaceutical field, the NPs 
were submitted to in vitro biological evaluation in order to investigate the 
cytocompatibility and bioactivity of the prepared nanosystems. 
The second research activity was carried out at Tsinghua University during a six months 
stage founded by the European Community. The research activities was aimed at the 
preparation of NPs by using an innovative biosurfactant, the small bacteria protein 
Phasin P (PhaP). PhaP is small bacteria amphiphilic protein, located on the surface of 
polyhydroxyalkanoates (PHAs), with the capability to non-specifically bind hydrophobic 
polymers. Biomolecules with amphiphilic proprieties, as well as PhaP, are classified as 
biosurfactants. Most of the synthetic surfactants currently used are petroleum based or 
chemically synthesized while PhaP can be conveniently produced by recombinant 
microorganisms and offering the possibility to reduce the costs of production and avoid 
the use of toxic chemical compounds. Two different polymeric materials, PLGA, and 
Poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx) were used for the NPs 
formulation. In order to prepare NPs endowed with targeting moieties, magnetite (Fe3O4) 
was loaded in the nanosystems as a physical targeting agent. This technology allows the 
possibility to drive NPs to a specific tissue in the body by the applications of simple 
external magnetic field. The prepared NPs were characterized in term of size, Z-potential 
and morphology. 
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II. GLOSSARY 
Polymers 
 
Poly (DL-lactide-co-glycolide) 
(PLGA) 
 
 
 
Poly (methacryloylglycylglycine-OHx-co-hydroxypropylmethacrylamide) 
Poly (Glyx-co-HPMAy) 
 
 
 
Glossary 
56 
 
 
Poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) 
(PHBHHx) 
 
Stabilizers 
 
 
Pluronic F-127 
 
 
 
O–Glycidyl–O–isopropylidenglycerol grafted β–cyclodextrin 
(GIG–βCD) 
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Reagents 
 
 
Tetrazolium salt (WST-1) 
 
 
 
Formazan (WST-1)
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III. LIST OF ABBREVIATIONS 
ATCC = American Type Culture Collection 
bFGF = Basic Fibroblast Growth Factor 
BMP = Bone Morphogenetic Proteins  
BSA = Bovine Serum Albumin  
CAD = Coronary Artery Disease 
CLI = Critical Limb Ischemia 
CT = Computed Tomography  
DCM = Dichloromethane  
DDS = Drug Delivery Systems  
DMEM = Dulbecco’s Modified Eagles Medium  
E.E. = Encapsulation Efficiency  
EGF = Epidermal Growth Factor 
ELISA = Enzyme-Linked Immuno Sorbent Assay 
FBS = Fetal Bovine Serum 
FDA = Food and Drug Administration 
GFs = Growth Factors 
GIG-βCD = O–Glycidyl–O–isopropylidenglycerol grafted β–cyclodextrin  
Hp = Heparin sodium salt 
HSA = Human Serum Albumin  
HSA-FITC = Human Serum Albumin - Fluorescein Isothiocyanate Conjugate  
IGF = Insulin-like Growth Factor 
IHD = Ischemic Heart Disease  
KGF = Keratinocyte Growth Factor 
MRI =Magnetic resonance imaging 
MSC = Mesenchymal Stem Cells 
N% = Number percent  
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NPs = Nanoparticles   
O/W = Oil in water emulsion  
ODNs = Oligodeoxyribonucleotides 
PAMAM = Poly (amidoamine) 
PBS = Phosphate Buffered Saline  
PCL = poly (ε-caprolactone) 
PCL-PEG-PCL = poly (ε-caprolactone) – poly (lactic acid) –poly (glycolic acid) 
PDGF = Platelet-derived Growth Factor 
PDGF-AB = Platelet-derived Growth Factor Isoform AB 
PDGFRs = PDGF Receptors  
PEI = Polyethylenimine  
PET = Positron-emission Tomography 
PG = Platelet Gels 
PGA = Poly (glycolic acid)  
PGA = Poly (glycolic acid) 
PhaP = Phasin P 
PHAs = Polyhydroxyalkanoates  
PHB = Poly-3-hydroxybutyrate 
PHBHHx = Poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) 
PHBV = Poly (3-hydroxybutyrate-co-3-hydroxyvalerate) 
PHO = Poly (3-hydroxyoctanoate) 
pI = Isoelectric point 
PI = Polydispersity Index 
PL = Platelet Lysate 
PLA = Poly (lactic acid) 
PLGA = Poly (Lactic-co-Glycolic Acid)  
PLL = Poly (L-lysine) 
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Poly (Gly-co-HPMA) = Poly (methacryloylglycylglycine-OHx-co-
hydroxypropylmethacrylamide)  
PPP = Platelet Poor Plasma  
PRP = Platelet Rich Plasma 
PVD = Peripheral Vascular Disease  
RES = Reticulo-endothelial System  
RISC = RNA-induced Silencing Complex 
RTKs = Tyrosine Kinase Receptors  
SD = Standard Deviation  
SEM = Scanning Electron Microscopy  
TEM = Transmission Electron Microscopy 
V% = Volume percent  
VEGF = Vascular Endothelial Growth Factor 
W/O = Water-in-oil emulsion   
W/O/W = Water-in-oil-in-water emulsion   
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2. Chapter II: PLGA based Nanoparticles Loaded with 
Growth Factors 
2.1. Introduction 
Wound healing is a complex and multipart process of restoring cellular structures and 
tissue after any injury. In human body wound healing process can be divided into 3 
distinct phases: the inflammatory phase, the proliferative phase and the remodeling 
phase [1]. Each phase is strictly regulated by various molecules, and growth factors 
(GFs) play a key role in this regulation process [2]. In particular, vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF) have been identified as 
the major regulators of vasculogenesis and angiogenesis during development, tissues 
repair and regeneration [3]. Wound healing occurs naturally in a healthy body, but it is 
compromised in people with diabetes or cardiovascular diseases. In recent years, the 
increase of incidence of these diseases, have led to discover the potential use of 
recombinant proteins as therapeutic agents. However the common administration routes 
for these new biotechnological drugs have some limitations. Their short half-life results 
in a low availability of GFs at the site of action that do not satisfy the physiological 
requirements for tissue repair [4]. A solution to these problems is given by controlled 
release technologies. Polymeric nanoparticles (NPs) constitute a versatile drug delivery 
system allowing for the tuning of the release profile of a drug by an appropriate selection 
of the carrier [5].   
Poly (lactic-co-glycolic acid) (PLGA) (Figure 1) has attracted immense interest over the 
last two decades, as a polymer for NPs preparation, due to its favorable properties such 
as good biocompatibility, biodegradability, low immunogenicity, low toxicity and 
mechanical strength [6]. Moreover, PLGA is easily formulated into different devices for 
delivering a variety of drugs such as vaccines, peptides, proteins, and macromolecules. 
The US Food and Drug Administration (FDA) have approved a very large number of 
drug delivery products based on this biomaterial [7]. PLGA is a copolymer synthesized 
from their cyclic dimers, (i.e. dl-lactide and glycolide), by ring-opening polymerization. 
During polymerization, successive monomeric units (of glycolic or lactic acid) are linked 
together in PLGA by ester linkages, thus yielding a linear, amorphous aliphatic polyester 
product [8]. PLGA in the body is hydrolyzed to produce the original monomers, lactic 
acid and glycolic acid, which are the byproducts of various metabolic pathways under 
normal physiological conditions. These monomers are easily metabolized via the Krebs 
cycle and eliminated. Thus, there is very minimal systemic toxicity associated with using 
PLGA for drug delivery or other biomedical applications [9].  
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Figure 1: Structure of PLGA 
In this study PLGA based NPs loaded with bFGF and VEGF and were prepared by a 
modified solvent diffusion technique. Heparin (Hp) and human serum albumin (HSA) 
were employed in NPs formulations as stabilizing agents. Nanoparticles were 
characterized in term of size, morphology, Z-potential and GFs encapsulation efficiency.  
2.2. Material 
PLGA [lactide:glycolide (50:50)] was purchased from Purac-Biochem (Amsterdam, 
NL). Pluronic® F-127 and Hp were obtained from Sigma-Aldrich (Milan, IT). HSA was 
kindly provided by Kedrion SpA (Castelvecchio Pascoli, Italy). The bFGF, VEGF and 
related ELISA kits were purchased from R&D Systems (Rovereto, IT). All solvents used 
were commercially available (Carlo Erba, Milan, Italy).  
2.3. Methods 
2.3.1. Nanoparticles formulations 
Preparation of Unloaded PLGA based NPs 
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 1.25% w/v of PLGA and 1.25% w/v of Pluronic F-127 were 
dissolved in 2 ml of dichloromethane (DCM). This organic solution was emulsified by 
vortex mixing for 30 seconds with 200 µl of deionized water for the preparation of 
unloaded NPs. 4 µg of Hp and 200 µg of HSA, added as stabilizing agents, were 
included in the 200µl of water before the emulsification processes. The resulting water-
in-oil emulsion was poured in to 25 ml of ethanol under magnetic stirring, and the 
resulting suspension was diluted with 25 ml of water. After solvent evaporation, under 
vacuum at 30˚C, NPs were concentrated in aqueous medium.  
Preparation of PLGA based nanoparticles loaded with VEGF and bFGF 
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 1.25% w/v of PLGA and 1.25% w/v of Pluronic F-127 were 
dissolved in 2 ml of DCM. The organic solution was mixed by vortex agitation for 30 s 
with 200 µl of a water solution containing: 300 ng of bFGF, 300 ng of VEGF, 4 µg of 
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Hp and 200 µg of HSA as stabilizing agents. The resulting water-in-oil emulsion was 
poured in to 25 ml of ethanol under magnetic stirring and the resulting suspension was 
diluted with 25 ml of water. After solvent evaporation under vacuum at 30˚C, NPs were 
concentrated in aqueous medium.  
2.3.2. Nanoparticles characterization 
Purification of nanoparticles 
The NPs suspensions were purified by using an ALC PK121R refrigerated centrifuge. 
NPs were centrifuge at 8000g for 1h at 4˚C. The obtained pellet of purified NPs was 
resuspended in appropriate media depending on their use. 
Dimensional analysis 
NPs size analyses were carried out by using a Coulter Beckman LS230 Laser Diffraction 
Particle Size Analyzer, equipped with small volume module plus. Samples were added 
into the cell until 30–50% obscuration of PIDS detector. Three runs were performed on 
each sample. 
Z-potential analysis  
Z-potential analyses were carried out by using Coulter Beckman Nano DelsaTM C at 
25˚C after evaluation of pH of NPs suspensions. Z-potential values were calculated as 
the mean value of 6 replications for each NPs formulation.  
Morphological analysis  
NPs morphology was evaluated by scanning electron microscopy (SEM) (JEOL 
LSM5600LV). The samples were prepared from purified and lyophilised NPs. Gold 
sputtering was performed before SEM analysis. 
Freeze-drying 
After freezing at –20 °C, nanoparticles were lyophilised in 5 Pascal Lio 5P lyophilisator, 
equipped with RV8 (Edwards) vacuum pump. 
Absorbance measurements on microplates 
Microplate absorbance measurements were performed by means of Benchmark Bio–Rad 
Microplate Reader. All data were processed by using Microplate Manager III (Biorad) 
and Igor Pro (Wavemetrics).  
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Determination of GFs encapsulation efficiency 
The supernatants of GFs loaded NPs were collected and used for evaluating the amounts 
of bFGF/VEGF that were not encapsulated into NPs by following the manufacturer 
instructions of the bFGF and VEGF ELISA kits respectively. The difference between the 
amount of bFGF/VEGF employed for the NPs preparation and the amount of 
bFGF/VEGF measured in NPs supernatant represented the bFGF/VEGF loaded into 
NPs. The encapsulation efficiency was calculated as percentage of bFGF/VEGF loaded 
in the NPs with respect to total amount of bFGF/VEGF added during the formulation of 
NPs. 
2.4. Results and Discussion 
Wound healing is quite a complicated process involving epidermal regeneration, 
fibroblast proliferation, neovascularization and synthesis [10]. Studies have shown that 
exogenous application of GFs may decrease the healing period and improve the quality 
of wound healing [11, 12]. In this study PLGA based NPs loaded with bFGF and VEGF 
were prepared by a modified solvent diffusion technique in order to obtain a GFs 
controlled delivery system to enhance wound healing. In order to improve the 
maintenance of bioactivity of the encapsulated GFs, Hp and HSA were employed in NPs 
formulations as stabilizing agents. The interaction of Hp with GFs has been shown to 
potentiate its activity and protect GFs from heat and enzymatic degradations [13], while 
HSA has a protective effect on GFs, since it reduces their exposure to water/organic 
solvent interfaces during NPs preparation [14].  
Preparation and characterization of PLGA based NPs  
Results related to the mean diameter size of unloaded NPs and bFGF/VEGF loaded NPs, 
their Z-potential values and GFs encapsulation efficiencies are reported in Table 1. NPs 
showed submicron size and monodispersed diameter distributions (Figure 2). The degree 
of interaction between biological systems and NPs depends mainly on their size. Indeed, 
NPs with smaller diameter size present larger contact areas with the target sites. Thus, 
the size of the developed nanosystems, below 150 nm, is appropriate for their future 
application, since they can promote a better and faster wound healing.  
 
 
 
 
Table 1: Size analysis, encapsulation efficiency and Z-potential of PLGA based NPs. 
Table 1 
Size ± S.D. 
(nm) 
Z-potential 
(mV) 
Encapsulation 
efficiency (%) 
bFGF VEGF 
Unloaded PLGA NPs 116 ± 16 -21.9 ± 0.52 - - 
bFGF/VEGF PLGA NPs 130 ± 18 -4.6 ± 0.06 75 % 97% 
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Figure 2: Diameter distribution of PLGA based NPs. Unloaded NPs (A) and bFGF/VEGF loaded 
NPs (B). 
NPs were characterized by negative Z-potential values. The measured Z-potential value 
of -21.9 ± 0.52 mV of the unloaded NPs, was in the range expected for colloidal systems 
based on polyesters loaded with Hp, Indeed, both the carboxylic moieties presents at the 
extremity of the polymer chains and the sulfated groups distributed along the backbone 
of the glycosaminoglycan chains, conferred negativity to the particles surface. The 
addition of GFs to the formulation significantly decreased its Z-potential value, from -
21.9 to -4.6 mV. The observed different values of Z-potential between unloaded and 
loaded NPs can be related to the presence of GFs bound to the particles surfaces that 
masked the anionic nature of Hp. This result confirmed that Hp effectively interacts with 
the GFs and suggested that the formation of Hp-GFs complexes is one of the factors that 
promoted the encapsulation of GFs. Z-potential data are commonly used to predict and 
control dispersion stability of NPs in aqueous dispersion state. High Z-potential values 
(positive or negative) lead to stable NPs suspensions, because the repulsion between the 
particles prevent their aggregation [15]. Thus we expect that these systems will be stable 
during storage.  
bFGF and VEGF showed different encapsulation efficiency probably due to the disparity 
in electrostatic charge of both molecules at NPs formulation pH (~5.5). VEGF is less 
positively charged than bFGF (pI = 7.3 for VEGF and pI = 9.6 for bFGF), and therefore, 
Hp could interact more with bFGF and enhance its encapsulation into NPs.     
The observed GFs encapsulation efficiency values were high, 75% for VEGF and 95% 
bFGF, making the NPs preparation methods adopted in this work suitable the preparation 
of nanosystems loaded with peptide or protein drugs. The obtained high encapsulation 
efficiencies could be attributed to the utilization of HSA in the formulation that was used 
as stabilizing agent. Likely, thanks to its amphiphilic proprieties, HSA shielded the GFs 
during NPs preparation, reducing their exposure to the water/oil interface [16].    
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The morphology of NPs was assessed by SEM. Figure 3 shows NPs with spherical shape 
and characterized by a well-dispersed distribution (Figure 3).  
 
Figure 3: Morphological analyses (SEM micrograph) of PLGA based NPs. Unloaded NPs (A) 
bFGF/VEGF loaded NPs (B). 
2.5. Conclusions  
This study was aimed at the preparation and characterization of PLGA based NPs as 
carriers for the administration of GFs, such as bFGF and VEGF. NPs were successfully 
prepared by a modified solvent diffusion technique.  
Hp and HSA were used as stabilizing agents for the NPs preparation, in order to obtain 
high GFs encapsulation efficiency and the stabilization of the resulting dispersions. In 
fact, Hp can stabilize GFs through the formation of Hp-GFs complexes that protect GFs, 
and help them to preserve their biological activity. HSA was used to avoid the 
interaction of bFGF/VEGF with the organic solvent during the NPs preparation. 
The prepared nanosystems were characterized by monomodal distribution of the 
diameters, submicron size (below to 150 nm), negative Z-potential values and good 
spherical morphology. No appreciable differences were observed between the unloaded 
and GFs loaded NPs. As exception, the Z-potential value of the GFs loaded NPs showed 
a significant decrease as confirm of the interaction between Hp and GFs. 
The high encapsulation efficiency of bFGF and VEGF into NPs makes these 
nanosystems very promising as GFs delivery devices, and in more broad terms for 
protein delivery. The successful encapsulation of both bFGF and VEGF might result in a 
synergic proangiogenic activity, important for the future application of these NPs system 
in the field of therapeutic angiogenesis, such as for the enhancement of wound healing.  
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3. Chapter III: PLGA based Nanoparticles Loaded with 
Platelet Lysate 
3.1. Introduction 
Significant clinical problems occur when blood supply is severally compromised, and 
tissues or organs oxygen deprivation (ischemia) can cause malfunctions and even the 
death of the patients. Angiogenesis is an important physiological process required for the 
growth of new blood vessels, and represents a fundamental route for wounds healing and 
for restoring blood flow to tissues after injury [1]. The regulation of the angiogenic 
process is complex and involves a mixture of molecules and cellular events, in which 
Growth Factors (GFs) play a fundamental role for the activation, proliferation and 
migration of the endothelial cells and subsequent generation of new blood vessel [2]. 
Platelet derivatives have been extensively used over the past twenty years to induce a 
functional angiogenesis in vitro [3, 4]. Platelet lysate (PL), which is an haemoderivative 
rich in GFs deriving from the lysis of platelets, has been proposed in clinical practice for 
the treatment of several ischemic conditions [5]. PL is obtained from Platelet Rich 
Plasma (PRP) after its freeze-thawing destruction. One of the advantages of using PL is 
that provides a mixture of autologous GFs in their biological concentration to assist the 
body in healing, and promotes vascularization with greater similarly to the natural 
processes [6]. Platelet-derived growth factor (PDGF) is the major constituent of PL. 
PDGF is a potent mitogen for cells of mesenchymal origin, including smooth muscle 
cells and glial cells and it plays a significant role in blood vessel formation [7]. PDGF 
family includes 5 isoforms: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-
DD, all expressed in platelets except PDGF-DD [8]. 
Protein drugs, such as GFs, can be easily chemically and enzymatically degraded, and 
may also lose their biological activity through conformational changes and aggregation. 
In order to maintain the biological activity of such biotechnological drugs they must be 
frequently administered. Nowadays, controlled delivery systems represent the best 
approach to protein drug administration [9]. In particular, protein drugs can be 
encapsulated within colloidal polymeric carriers, such as nanoparticles (NPs), which can 
protect them against degradation and ensure their transport and delivery to the specific 
site of action at a controlled rate [10]. 
Poly (lactic-co-glycolic acid) (PLGA) has attracted immense interest over the last two 
decades for NPs preparation due to its favorable properties such as good 
biocompatibility, biodegradability, low immunogenicity, low toxicity and mechanical 
strength [11, 12]. The US Food and Drug Administration (FDA) approved a very large 
number of drug delivery products based on PLGA [13].   
Fibrin gel, prepared from fibrinogen and thrombin, the key proteins involved in blood 
clotting, is one of the first biomaterials used to prevent bleeding and promote wound 
healing [14]. Due to its excellent features, such as elasticity and capability to easy self-
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assemble under physiological conditions, fibrin gel is a potent tool for clinical 
applications [15]. However, one of the disadvantages of using fibrin gel as a drug 
delivery system is that most of entrapped drug is released in less than several hours [16]. 
Recently, to overcome this problem NPs were incorporated into fibrin gels to obtain 
combined controlled drug delivery devices that allow a better control over the drug 
release profile [17-19]. 
In this study we report the preparation of PLGA based NPs loaded with Platelet Lysate 
(PL) as source of angiogenic related GFs by a modified solvent diffusion technique. 
Different concentrations of PLGA and surfactant were used to determine the best 
conditions for the preparation of PL loaded NPs. The prepared NPs were incorporated 
into a fibrin matrix with the intention of producing a controlled system able to delivery 
PL directly to the wound site as skin dressing, for treatment of chronic wound. 
In order to ensure the maintenance of bioactivity of the encapsulated PL, heparin (Hp) 
was used as stabilizing agent. Several studies demonstrated that GFs present in their 
architecture an heparin-binding domain [20, 21] and the interaction of Hp with GFs has 
shown to potentiate its activity and to protect GFs from heat and enzymatic degradation 
[22, 23].  
The prepared NPs were submitted to physical and chemical characterizations. The mean 
particles size, stability of NPs and Z-potential values were evaluated by dynamic light 
scattering and electrophoretic light scattering. Morphological analyses were performed 
by scanning electron microscope (SEM). Colorimetric detection method was used to 
investigate the total protein loading into NPs and encapsulation efficiency. ELISA assay 
was used to elucidate the specific growth factor's encapsulation efficiency. The study 
was carried out using PDGF as reference growth factor in PL. Release kinetic profile 
was investigated by using a model protein drug, fluorescein isothiocyanate conjugate 
human serum albumin (HSA-FITC) under physiological conditions.  
3.2. Material 
PLGA50:50 [lactide:glycolide (50:50); inherent viscosity CHCl3 0.5g/dl: 0.4 dl/g ] was 
obtained from Purac-Biochem (Amsterdam, NL). HSA, PRP and fibrin gel kits were 
kindly provided by Kedrion SpA (Castelvecchio Pascoli, Italy). Pluronic® F-127, HSA-
FITC and Hp were purchased from Sigma-Aldrich (Milan, Italy). The Micro BCA 
Protein Assay kit was obtained from Pierce (Rockford, IL). Human PDGF-AB ELISA 
assay kit was purchased from Abnova (Taipei, Taiwan). Phosphate Buffer Saline 
solution (PBS 10X) was prepared by dissolving 2.0 g of KCl, 2.0 g of KH2PO4•H2O, 80 
g of NaCl, and 15.6 g of Na2HPO4•12H2O in 1 liter of distilled water. The pH was 
adjusted to 7.4 with 10 N NaOH and the resulting solution was sterilized in autoclave 
(121°C for 20 min) before use and storage. Physiological solution was prepared by 
dissolving 9.0 g of NaCl in 1 litre of distilled water. The solution was sterilized in 
autoclave (121°C for 20 min) before use and storage. All solvents used were 
commercially available (Carlo Erba, Milan, Italy).  
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3.3. Methods 
3.3.1. Preparation of Platelet Lysate 
Platelet Lysate (PL) was prepared as reported by following: platelets presents in PRP 
were isolated by centrifugation at 10000g for 15 minutes, at 4˚C, resuspended in aqueous 
medium and submitted to a freeze-thaw cycle (in order to obtain platelets lyses and 
subsequent growth factors release) and finally centrifuged at 10000g for 15 minute, 4˚C. 
The GFs water rich supernatant was used for NPs preparation.  
3.3.2. Preparation of nanoparticles  
Preparation of Unloaded PLGA based nanoparticles  
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 2.5% w/v or 1.25% w/v of PLGA and 2.5% w/v or 1.25% 
w/v of Pluronic F-127 were dissolved in 2 ml of dichloromethane (CH2Cl2). This organic 
solution was emulsified by vortex mixing for 30 seconds with 200 µl of deionized water 
for the preparation of unloaded NPs. The resulting water-in-oil emulsion was poured in 
to 25 ml of ethanol under magnetic stirring, and the resulting suspension was diluted 
with 25 ml of water. After solvent evaporation, under vacuum at 30˚C, NPs were 
concentrated in aqueous medium.  
Preparation of PLGA based nanoparticles loaded with Human Serum Albumin 
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 2.5% w/v or 1.25% w/v of PLGA and 2.5% w/v or 1.25% 
w/v of Pluronic F-127 were dissolved in 2 ml of dichloromethane (CH2Cl2). This organic 
solution was emulsified by vortex mixing for 30 seconds with 200 µl of HAS (0.5%) for 
the preparation of HSA loaded NPs. The resulting water-in-oil emulsion was poured in 
to 25 ml of ethanol under magnetic stirring, and the resulting suspension was diluted 
with 25 ml of water. After solvent evaporation, under vacuum at 30˚C, NPs were 
concentrated in aqueous medium.   
Preparation of PLGA based nanoparticles loaded with Platelet Lysate  
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 2.5% w/v or 1.25% w/v of PLGA and 2.5% w/v or 1.25% 
w/v of Pluronic F-127 were dissolved in 2 ml of dichloromethane (CH2Cl2). This organic 
solution was emulsified by vortex mixing for 30 seconds with 200 µl of PL for the 
preparation of PL loaded NPs. The resulting water-in-oil emulsion was poured in to 25 
ml of ethanol under magnetic stirring, and the resulting suspension was diluted with 25 
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ml of water. After solvent evaporation, under vacuum at 30˚C, NPs were concentrated in 
aqueous medium.  
Preparation of Unloaded PLGA based nanoparticles in presence of Heparin 
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 1.25% w/v of PLGA and 1.25% w/v of Pluronic F-127 were 
dissolved in 2 ml of dichloromethane (CH2Cl2). This organic solution was emulsified by 
vortex mixing for 30 seconds with 200 µl of deionized water for the preparation of 
unloaded NPs. 2 µg of Hp, added as stabilizing agent, was included in the 200µl of water 
before the emulsification processes. The resulting water-in-oil emulsion was poured in to 
25 ml of ethanol under magnetic stirring, and the resulting suspension was diluted with 
25 ml of water. After solvent evaporation, under vacuum at 30˚C, NPs were concentrated 
in aqueous medium.  
Preparation of PLGA based nanoparticles loaded with Platelet Lysate in presence of 
Heparin  
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 1.25% w/v of PLGA and 1.25% w/v of Pluronic F-127 were 
dissolved in 2 ml of dichloromethane (CH2Cl2). This organic solution was emulsified by 
vortex mixing for 30 seconds with 200 µl of PL for the preparation of PL loaded NPs. 2 
µg of Hp, added as stabilizing agent, was included in the 200µl of PL solution, before 
the emulsification processes. The resulting water-in-oil emulsion was poured in to 25 ml 
of ethanol under magnetic stirring, and the resulting suspension was diluted with 25 ml 
of water. After solvent evaporation, under vacuum at 30˚C, NPs were concentrated in 
aqueous medium.  
Preparation of PLGA based nanoparticles loaded with Fluorescein Isothiocyanate 
Conjugate Human Serum Albumin 
PLGA50:50/Pluronic based NPs (in ratios 1:1) were prepared by a modified solvent 
diffusion technique. Briefly, 1.25% w/v of PLGA and 1.25% w/v of Pluronic F-127 were 
dissolved in 2 ml of dichloromethane (CH2Cl2). This organic solution was mixed by 
vortex agitation for 30 seconds with 200 µl of HSA-FITC (1 mg) for the fluorescent 
marker loaded NPs. The resulting water-in-oil emulsion was poured in to 25 ml of 
ethanol under magnetic stirring, and the resulting suspension was diluted with 25 ml of 
water. After solvent evaporation, under vacuum at 30˚C, NPs were concentrated in 
aqueous medium.  
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3.3.3. Nanoparticles characterization 
Purification of nanoparticles 
The NPs suspensions were purified by using an ALC PK121R refrigerated centrifuge. 
NPs were centrifuge at 8000g for 1h at 4˚C. The obtained pellet of purified NPs was 
resuspended in appropriate media depending on their use. 
 
Dimensional analysis 
NPs size analyses were carried out by using a Coulter Beckman LS230 Laser Diffraction 
Particle Size Analyzer, equipped with small volume module plus. Samples were added 
into the cell until 30–50% obscuration of PIDS detector. Three runs were performed on 
each sample. 
Z-potential analysis  
Z-potential analyses were carried out by using Coulter Beckman Nano DelsaTM C at 
25˚C after evaluation the of the NPs suspensions pH. Z-potential values were calculated 
as the mean value of 6 replications for each NPs formulation.  
Morphological analysis  
The NPs morphology was evaluated by scanning electron microscopy (SEM) (JEOL 
LSM5600LV). The samples were prepared from purified and lyophilised NPs. Gold 
sputtering was performed before SEM analysis. 
Freeze-drying 
After freezing at –20 °C, nanoparticles were lyophilised in 5 Pascal Lio 5P lyophilisator, 
equipped with RV8 (Edwards) vacuum pump. 
Absorbance measurements on microplates 
Microplate absorbance measurements were performed by means of Benchmark Bio–Rad 
Microplate Reader. All data were processed by using Microplate Manager III (Biorad) 
and Igor Pro (Wavemetrics). 
Determination of protein encapsulation efficiency and loading 
Proteins encapsulation efficiency was calculated from the proteins amount that was 
detected in the supernatant recollected after centrifugation of the NPs samples. Standard 
micro BCA protein assay was used to determine the amount of free proteins (HSA) in 
the NPs supernatant and the amount of proteins contained in the PL employed for the 
NPs preparation. The difference between the amount of protein employed for the NPs 
preparation, and the amount of proteins measured in NPs supernatant represented the 
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proteins loaded into NPs. This value was necessary for the calculation of the 
encapsulation efficiency and drug loading. The encapsulation efficiency was calculated 
as percentage of proteins loaded in the NPs with respect to total amount of proteins 
added during the formulation of NPs (Equation 1). Drug loading was calculated as 
percentage of proteins loaded in NPs with respect to the dry weight of recovered NPs 
(Equation 2). A calibrations curve of Bovine Serum Albumin (BSA) was prepared by 
following the manufacturer instructions. All samples were measured at 565nm. Mean 
values were obtained from three different batches. 
Equation 1: 
 
 
 
Equation 2:  
 
 
In order to determine the percentage of released protein, we evaluated the HSA-FITC 
loading % of the 2.6 ± 0.5% in the PLGA based NPs. 
Encapsulation efficiency of Platelet Derived Growth Factor Isoform AB 
The amount of PDGF-AB in the NPs was determined both in PL and hydrolyzed NPs 
samples. Briefly, 1mg of the isolated NPs was hydrolyzed in 1ml of NaOH (0.05N). This 
hydrolytic process was maintained under stirring for 1 hour at room temperature. The 
obtained samples were opportunely diluted and analyzed by ELISA assay kit. Mean 
values were obtained from three different batches.   
Stability of nanoparticles  
Stability of NPs in water was investigated by dynamic light scattering using Coulter 
Beckman LS230 Laser Diffraction Particle Size Analyzer. Nanoparticles suspensions 
were stored under static conditions at 4˚C for 4 weeks. The average size was analyzed at 
specified time intervals, within one month, in loaded and unloaded NPs prepared in 
presence or absence of Hp.  
In vitro HSA-FITC release kinetics from PLGA nanosystems  
In order to determine the percentage of released protein, we first evaluated the HSA-
FITC loading into NPs by an indirect method. The unloaded drug was quantified by 
measuring the free drug found in the supernatant of the prepared drug-loaded NPs 
spectrofluorimetrically with excitation and emission wavelengths of 485 and 535 nm, 
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respectively. Using the amount of unloaded drug, the drug-loaded quantity was 
determined (total drug added - free drug). HSA-FITC loading was estimated in 2.6 ± 
0.5% into the PLGA based NPs. 
The HSA-FITC loaded NPs were resuspended in 10ml of Phosphate Buffer Saline (PBS, 
0.01M, pH 7.4), and incubated at 37˚C under magnetic stirring. At appropriated time 
points, samples were centrifuged at 8000g for 15 minutes at room temperature and the 
supernatant were collected for the determination of HSA-FITC release. NPs pellets were 
then resuspended with 10 ml of fresh PBS. The released HSA-FITC concentration in the 
PBS medium was assessed spectrofluorimetrically.  
Incorporation of nanoparticles into fibrin matrix  
The fibrin matrix kit consisted of thrombin and fibrinogen in separate vials, plus separate 
solutions of calcium chloride (CaCl2) and potassium dihydrogen phosphate (KDP). The 
PL loaded NPs incorporated fibrin gel was prepared as follows. Thrombin was 
reconstituted in a CaCl2 solution and then drawn into a syringe. Fibrinogen, containing 
Factor XIII, was reconstituted in the KDP solution in order to obtain 30 IU/ml of 
fibrinogen concentration and then 10 mg of PL loaded NPs were added to this 
suspension. The PL-NPs-fibrinogen suspension was kept under magnetic stirring until 
the complete dissolution of NPs. The NPs- fibrinogen suspensions were placed 
respectively into 24-well plate and when the thrombin solution was added, the 
gelification phenomenon occurred immediately due to the conversion of fibrinogen to 
fibrin, and the plate was incubated at 37 ˚C for 1 h to complete polymerization. The 
fibrin matrices were prepared with two different concentrations of thrombin, 625 UI/ml 
and 100 UI/ml respectively, in order to study the effect of thrombin concentrations on 
the fibrin matrix formation.   
3.4. Results and Discussion 
In this work, we prepared platelet’s GFs loaded PLGA based nanoparticles by a 
modified solvent diffusion technique. This technique is very suitable for the 
encapsulation of proteins, because avoid the use of high energy procedures that could 
cause structural damages of the proteins [24]. PL obtained from several purification steps 
of PRP was used as source of GFs.  
NPs formulations studies, comprising the variation of the polymer concentrations for the 
NPs preparation, were performed in order to define the best formulation conditions. HSA 
was used as model drug with the intention of obtaining information on the suitability and 
versatility of the employed method for the encapsulation of proteic drugs.  
Characterization of PLGA based NPs  
NPs were prepared by using 2.5% w/v and 1.25% w/v of PLGA as matrix. All prepared 
nanosystems were characterized by a narrow monomodal distribution of diameters 
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(Figure 1). Table 1 shows the mean diameters size, encapsulation efficiency and PL 
loading of the PLGA based NPs. No appreciable size differences were evidenced 
between unloaded, HSA and PL loaded NPs.  
The morphological evaluations were carried out by SEM and the obtained results are 
shown in Figure 2. All the prepared nanosystems showed similar physical characteristics 
and the presence of HSA and PL did not affect the diameter distributions and size of NPs 
that resulted below 200 nm. All the prepared NPs were characterized by good spherical 
shape (Figure 2).   
  
 
Figure 1: Diameter distribution of PLGA based NPs. Unloaded NPs (A), HSA loaded NPs (B) and 
PL loaded NPs (C) prepared with 2.5% w/v of PLGA. Unloaded NPs (D), HSA loaded NPs (E) 
and PL loaded NPs (F) prepared with 1.25 % w/v of PLGA.   
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Table 1: Dimensional analysis, encapsulation efficiency and loading of PLGA based NPs. 
 
 
Figure 2: Morphological analyses (SEM micrograph) of PLGA based NPs. Unloaded NPs (A) 
HSA loaded NPs (B) and PL loaded NP (C) prepared with 2.5% w/v of PLGA. Unloaded NPs (D), 
HSA loaded NPs (E) and PL loaded NPs (F) prepared with 1.25 % w/v of PLGA.   
Based on these results, the NPs formulated with 1.25% w/v of PLGA were chosen for 
further studies since they were characterized by good proprieties and allowed to reduce 
the amount of polymeric material employed, thus reducing production costs. Moreover, 
lower amounts of polymers means reducing the potential toxicity risks of prepared NPs. 
Hp was used as stabilizing agent for the preparation of the following set of NPs 
formulations, in order to improve the maintenance of bioactivity of the encapsulated PL. 
The unloaded and PL loaded PLGA based NPs, prepared in presence of Hp were 
characterized by a monomodal distribution of diameters (Figure 3) and spherical 
morphology (Figure 4). No considerable difference with the NPs prepared with the 
Table 1 
Size ± S.D. 
(nm) 
Encapsulation 
efficiency (%) 
Loading (%) 
2.5% w/v PLGA 
based NPs 
Unloaded NPs 143 ± 26 - - 
HSA loaded 
NPs 
140 ± 29 53 ± 2% 2.25 ± 0.2% 
PL loaded NPs 167 ± 41 85 ± 4% 1.73 ± 0.3% 
1.25% w/v 
PLGA 
based NPs 
Unloaded NPs 118 ± 16 - - 
HSA loaded 
NPs 
139 ± 20 79 ± 5% 2.10 ± 0.4% 
PL loaded NPs 130 ± 18 89 ± 6% 2.21 ± 0.3% 
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addition of Hp was evidenced. Table 1 shows the mean diameters size, Z-potential, 
encapsulation efficiency and PL loading of the PLGA based NPs prepared in presence of 
Hp. 
 
Figure 3: Diameter distribution of PLGA based NPs prepared with 1.25% w/v of polymer and in 
presence of Heparin. Unloaded NPs (A) and PL loaded NPs (B).  
 
Figure 4: Morphological analyses (SEM micrograph) of PLGA based NPs prepared with 1.25% 
w/v of polymer and in presence of Heparin. Unloaded NPs (A) and PL loaded NP (B).   
 
Table 2: Size analysis, encapsulation efficiency, loading and Z-potential of PLGA based NPs 
prepared in absence and presence of Heparin. 
Table 2 
Size ± S.D. 
(nm) 
Encapsulation 
efficiency (%) 
Loading 
(%) 
Z-potential ± 
S.D. (mV) 
1.25% w/v PLGA 
based NPs prepared in 
absence of Heparin 
Unloaded 
NPs 
See table 1 
-20,6 ± 1.26 
PL loaded 
NPs 
-9.7 ± 0.36 
1.25% w/v PLGA 
based NPs prepared in 
presence of Heparin 
Unloaded 
NPs 
143 ± 20 - - -26.6 ± 0.59 
PL loaded 
NPs 
137 ± 19 73 ± 1.8 % 
1.9 ± 
0.04% 
-16.7 ± 0.23 
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The size of NPs resulted below 200 nm and was not affected by the presence of Hp.  
All the prepared NPs were characterized by negative Z-potential values. These negative 
surface charges can be attributed to the presence of the end carboxyl groups of the 
polymer on the NPs surfaces. The Z-potential is an indication of the repulsive force that 
is present on nanoparticle surface and can be used to predict the long-term stability of the 
NPs. If all the particles in suspension have a large negative or positive zeta potential then 
they will tend to repel each other minimizing the tendency to aggregate. However, if the 
particles have low zeta potential values then there is no force that prevent the particles 
coming together and flocculating [25, 26]. 
The presence of Hp affected PL loading and encapsulation efficiency. Indeed, the 
addition of the stabilizing agent decreased the drug loading from 2.2 ± 0.3% to 1.9 ± 
0.04%, and the encapsulation efficiency from 89 ± 6% to 73 ± 1.8 %. We observed that 
the particles Z-potential was reduced when the NPs were prepared in presence of Hp, 
suggesting that part of the encapsulated Hp was anchored onto the NPs surface, 
increasing its anionic nature. Thus, it is likely that the addition of Hp inhibited the 
loading of PL proteins that are negatively charged at the NPs formulative conditions 
(pH: 6). The loading of these proteins, such as glycoprotein IIb/IIIa (pI = 5) [27], was 
hampered by electrostatic repulsions. On the contrary, proteins characterized by a 
positive charge at this pH, such as GFs (e.g. PDFG, VEFG, bFGF pI= 7-10) [28], were 
attracted by Hp and their encapsulation was increased. Furthermore, the PDGF family 
presents an efficient binding site for Hp, and the formation of an Hp-GF complex could 
have further favored its incorporation into NPs [23]. In order to verify this hypothesis, 
the PDGF-AB was selected for the following analysis.  
Encapsulation efficiency of Platelet Derived Growth Factor Isoform AB 
In order to specifically evaluate the effect of Hp on the encapsulation efficiency of the 
GFs, we selected PDGF-AB as reference GF in PL. This analysis was carried out by 
PDGF-AB human ELISA kit and the results are reported in Table 3. The detected 
amount of PDGF-AB in PL was 7000 ng/ml. The encapsulation efficiency of PDGF-AB 
was effectively increased from 14% to 31% when Hp was added to the formulation.  
Table 3 
PDGF-AB 
(ng/ml of NPs 
suspension) 
PDGF-AB  
EE% 
PDGF-AB in PL 7000 ng/ml - 
PL loaded PLGA based NPs 8.8 14 % 
PL loaded PLGA based NPs with Heparin 21.3 31 % 
 
Table 3: Encapsulation efficiency of PDGF-AB in the PLGA based NPs prepared in absence and 
presence of Heparin. 
Chapter III: PLGA based Nanoparticles loaded with Platelet Lysate 
80 
 
Stability of nanoparticles  
A successful drug delivery system requires efficiency and stability during storage, thus 
stability studies are imperative for new pharmaceutical products. In these studies we 
analyzed the stability of unloaded and PL loaded NPs, prepared in absence and presence 
of Hp. NPs were stored in aqueous medium at 4°C by monitoring their size for 4 weeks. 
Results showed that, after 4 weeks, the size of PL loaded NPs remain stable for all the 
NPs formulations (Figure 5). The stability of prepared NPs could be attributed to their 
surface charge, since the repulsion forces between the NPs prevent their aggregation.  
 
Figure 5: Stability of unloaded and PL loaded PLGA based NPs prepared in absence and presence 
of Hp in water.  
In vitro HSA-FITC release kinetics from PLGA nanosystems  
HSA-FITC was selected as a model protein for the in vitro release studies. The release 
profile of the prepared nanosystem was determined in PBS 1X medium at 37˚C to 
reproduce the physiological conditions. The result of the release studies are displayed in 
Figure 6. The release kinetic was characterized by two phases of release, an initial burst 
(40%) followed by sustained release up to 90% in 13 days. These results are in 
accordance with the literatures [29-31]. Release profiles provided by PLGA based NPs 
are typically characterized by a biphasic curve: (a) in the first phase, an initial drug 
release is associated to the diffusion of the encapsulated drug localized onto the NPs 
surface. (b) In the second phase, drug is released progressively [32].  
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Figure 6: HSA-FITC release profile from PLGA based NPs. 
 
Incorporation of nanoparticles into fibrin matrix  
Fibrin gels loaded with the developed PL-NPs were prepared in order to obtain a 
controlled release device that can be topically applied at the wound site. Gels were 
obtained by using two different concentrations of thrombin (Figure 7). The gelification 
phenomenon occurred immediately due to the conversion of fibrinogen into fibrin and 
PL-NPs were successfully entrapped into the matrices.  
The composition of fibrin gel, in terms of fibrinogen and thrombin concentrations, 
represents an important parameter that determine the release rate from fibrin matrices 
[15]. As the concentration of thrombin is increased in the composite gel, a dense cross-
linked fibrin network is formed, and the release from the fibrin network is slowed [33].  
We examined the concentrations effect of thrombin on the PL-NPs-loaded fibrin gel 
formation in order to obtain fibrin matrices with different release properties. No 
significant difference in fibrin matrices formation were observed between the two 
preparations with different thrombin concentrations; the prepared fibrin matrices resulted 
equally suitable to be used as devices for PL-NPs incorporation, thus offering the 
possibility to modulate the PL release at a desired rate.  
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Figure 7: Fibrin matrices with PL loaded PLGA based NPs prepared with 625 UI/ml (A) and 100 
UI/ml (B) of thrombin respectively.  
3.5. Conclusions  
This study was aimed at the preparation and characterization of PLGA based NPs as 
carriers for the administration of PL. NPs were successfully prepared by a modified 
solvent diffusion technique. Initially we prepared NPs with two different polymer and 
surfactant concentrations in order to select the optimal formulation conditions. Based on 
these results, the formulations with 1.25% w/v of polymer and surfactant were chosen 
for the further analysis. 
Hp was used as stabilizing agent for the NPs preparation, in order to obtain an 
improvement of PL encapsulation and stabilization of the dispersions. The prepared 
nanosystems were characterized by monomodal distribution of the diameters, submicron 
size (below to 200 nm), negative Z-potential values and good spherical shape. The 
addition of Hp to the formulations did not affect the dimensions and morphologies of the 
prepared nanosystems. On the contrary, Z-potential values were increased while the 
encapsulation efficiency and drug loading were decreased. Likely, the high negative 
charge density of Hp increased the negativity of the particles, and inhibiting, by 
electrostatic repulsions the encapsulation of the negatively charged PL proteins. As 
confirm, positively charged proteins such as PDGF-AB, displayed an opposite behavior. 
Indeed, PDGF-AB was selected to specifically evaluate the effect of Hp on 
encapsulation efficiency, and we observed an increase of the EE% value which rose 
from 14% to 30%. 
The stability of the prepared NPs was studied over 4 weeks. The nanosystems showed a 
good stability in water and maintained their size below 200 nm, with no appreciable 
difference between the loaded and unloaded NPs both in presence and absence of Hp. In 
vitro release studies were carried out by using HSA-FITC NPs drug release was 
characterized by an initial burst followed by sustained release up to 90% in 13 days. The 
developed NPs were successfully incorporated into fibrin matrices prepared by using two 
different concentrations of thrombin.  
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The developed combined-system seems to be promising for the delivery of PL. It 
possesses the advantages of both PLGA based NPs and ﬁbrin gel scaffolds, including: 
protection of PL from proteolysis; sustained and controlled release; biologic 
adhesiveness and biocompatibility. This is especially true for topical applications 
systems, for whom the rate of GFs release have a critical importance in the promotion of 
the wounds healing process. 
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4. Chapter IV: Poly (Gly25-co-HPMA75) based 
Nanoparticles Loaded with Platelet Lysate  
4.1. Introduction 
Therapeutic angiogenesis is a promising therapy based on the stimulation of 
neovascularization, which can be used in the treatment or prevention of clinical 
situations characterized by local hypovascularity. The angiogenic process involves 
growth factors (GFs) activation of endothelial cells that leads to proliferation, migration 
and stabilization of vessels to form a mature vascular network [1].  
Nowadays, platelets derivates are under investigations in the field of therapeutic 
angiogenesis as one of the most concentrated natural source of GFs [2]. Platelet lysate 
(PL), which is an haemoderivative rich in GFs deriving from the lysis of platelets, has 
been proposed in clinical practice for the treatment of several ischemic conditions [3]. 
PL is obtained from Platelet Rich Plasma (PRP) after its freeze-thawing destruction. One 
of the advantages of using PL is that it provides a mixture of autologous GFs in their 
biologically concentration to assist the body in healing, and promotes vascularization 
with greater similarly to the natural processes [4]. 
The successful administration of therapeutic proteins, such as GFs, are often impeded by 
several difficulties, bound to their insufficient stability and shelf life, costly production, 
immunogenic and allergic potential, as well as poor bioavailability and sensitivity 
towards proteases. Nowadays, controlled delivery systems represent the best approach to 
protein drug administration. In particular, protein drugs can be encapsulated within 
injectable colloidal polymeric carriers, such as nanoparticles (NPs), which can protect 
them against degradation and ensure their transport and delivery to the specific site of 
action at a controlled rate [5]. 
Hydroxypropyl methacrylamide (HPMA) based co-polymers are a class of biomedical 
polymers obtainable through synthetic pathways. They can be tailored to their final 
specific application by modulating the choice of the co-monomers and are amenable to 
bio-functionalization with biological targeting moieties thanks to the presence of reactive 
functional groups [6]. Water-soluble polymers such as HPMA copolymers are frequently 
employed as drug carriers because there are able to improve the solubility of 
hydrophobic compounds, to reduce non-specific toxicity, and to increase the therapeutic 
index of low molecular weight anticancer drugs [6, 7]. 
The hydrophilicity of the polymer was balanced by adding different percentages of 
biodegradable oligopeptide side-chains to the HPMA backbone [8]. These side-chains 
had also the potential to be used as drug attachment/release sites [9]. However, the 
HPMA backbone is not biodegradable and consequently the molecular masses of HPMA 
co-polymers have been limited to 40 kDa or below to ensure renal elimination [10]. 
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These characteristics, along with the fundamental properties of biocompatibility, endow 
these copolymers with good chances of success as matrices for NPs formulation.  
In our laboratories we successfully prepared NPs based on the co-polymers poly 
(methacryloylglycylglycine-OHx-co-hydroxypropylmethacrylamidey) [poly (Glyx-co-
HPMAy] (Figure 1) loaded with Human Serum Albumin (HSA) as a model protein drug 
[11].  
 
Figure 1: Structure of poly (Glyx-co- HPMAy). 
Fibrin gel, a network formed when fibrinogen is activated by thrombin, represents 
another potential drug-delivery system. Due to its excellent features, such as elasticity 
and capability to easy self-assemble under physiological conditions, fibrin gel is a potent 
tool for clinical applications [12]. 
Fibrin gel with loaded with a drug can be easily injected, forming a drug reservoir for 
local delivery at the desired site. In several studies, fibrin gel was used as matrix to 
deliver GFs [13, 14]. However, due to GFs instability when administrated in gel 
formulations [15], systems based on the incorporation of GFs loaded NPs into fibrin gels 
are under investigation [16].   
The objective of the present study was to investigate the suitability the copolymer poly 
(methacryloylglycylglycine-OH25-co-hydroxypropylmethacrylamide75) [poly (Gly25-co-
HPMA75)] for the preparation of NPs loaded with PL as a source of GFs. PL used for 
NPs preparations was obtained from several purification steps of PRP, the portion of 
plasma enriched with platelets.  
The prepared NPs were designed to be subcutaneously injected into ischemic limbs. 
According to this future application, we studied the possibility to include the prepared 
PL-NPs in a fibrin matrix. The prepared NPs should be characterized by a fast release 
profiles since the drug will be further retain by the fibrin matrix before reaching the site 
of action. This system can be defined as combined injectable controlled delivery system 
for the release of PL directly at the ischemic site.  
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In order to ensure the maintenance of bioactivity of the encapsulated GFs, heparin 
sodium salt (Hp) was used as stabilizing agent during NPs preparation. Several studies 
demonstrated that GFs present in their architecture a heparin-binding domain [17, 18] 
and the interaction of Hp with GFs showed to potentiate its activity and to protect GFs 
from heat and enzymatic degradation [19, 20]. 
The prepared NPs were submitted to physical and biological characterizations. The mean 
particles size and stability of NPs were evaluated by dynamic light scattering. 
Morphological analyses were performed by Scanning Electron Microscope (SEM). 
Colorimetric detection method was used to evaluate the protein loading into NPs and the 
process encapsulation efficiency. Release kinetic profile was carried out by using 
Fluorescein Isothiocyanate Conjugate Human Serum Albumin (HSA-FITC) as model 
protein drug. Moreover, a careful in vitro biological investigation of the cytotoxicity of 
the prepared NPs was carried out.   
4.2. Material 
Poly (Gly25-co-HPMA75) and 1-O-glycidyl-2,3-o- isopropylidenglycerol-(β-
cyclodextrin) (GIG-(βCD) were supplied by Polymer Laboratories Ltd. (UK). HSA, PRP 
and fibrin gel kit were kindly provided by Kedrion SpA (Castelvecchio Pascoli, Italy). 
HSA-FITC and Hp were purchased from Sigma-Aldrich (Milan, Italy). The Micro BCA 
Protein Assay kit was obtained from Pierce (Rockford, IL). Phosphate Buffer Saline 
solution (PBS 10X) was prepared by dissolving 2.0 g of KCl, 2.0 g of KH2PO4•H2O, 80 
g of NaCl, and 15.6 g of Na2HPO4•12H2O in 1 liter of distilled water. The pH was 
adjusted to 7.4 with 10 N NaOH and the resulting solution was sterilized in autoclave 
(121°C for 20 min) before storage. PBS 10X was used diluted ten folds with sterile 
distilled water (PBS 1X) Physiological solution was prepared by dissolving 9.0 g of 
NaCl in 1 liter of distilled water. The solution was sterilized in autoclave (121°C for 20 
min) before use and storage. Dulbecco’s Modified Eagle’s Medium (DMEM), Bovine 
Calf Serum (BCS), Penicillin/Streptomycin (P/S) solutions were purchased from Gibco. 
Complete Dulbecco’s Modified Eagle’s Medium (Complete DMEM) was prepared by 
adding penicillin (100 U/mL), streptomycin (100μg/ mL), glutamine (4 mM) and 10% 
calf serum to DMEM. The Balb/3T3 Clone A31 (ATCC CCL163) mouse embryo 
fibroblast cell line was purchased from ATCC (American Tissue Culture Collection) and 
propagated following the instructions provided by the supplier. The cell proliferation 
reagent WST-1 was purchased from Roche Molecular Biochemicals and stored at -20°C 
in the dark. All solvents used were commercially available (Carlo Erba, Milan, Italy).  
4.3. Methods 
4.3.1. Preparation of Platelet Lysate 
Platelet Lysate (PL) was prepared as reported by following: platelets presents in PRP 
were isolated by centrifugation at 10000g for 15 minutes, at 4˚C, resuspended in aqueous 
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medium and submitted to a freeze-thaw cycle (in order to obtain platelets lyses and 
subsequent GFs release) and finally centrifuged at 10000g for 15 minute, 4˚C. The GFs 
water rich supernatant was used for NPs preparation.  
4.3.2. Preparation of nanoparticles 
Preparation of Unloaded Poly (Gly25-co-HPMA75) based nanoparticles  
The preparation of Poly (Gly25-co-HPMA75) based NPs was carried out by co-
precipitation technique [11]. In brief, 12.5 mg of polymer was dissolved in 2 ml of a 
water/ethanol solution (1:4) and was added by a syringe equipped with 22 G needle to a 
solution of 7 mg of GIG-βCD, 5 mg of HSA in 5 ml of distilled water kept under 
magnetic stirring at room temperature.  
Preparation of Poly (Gly25-co-HPMA75) based nanoparticles loaded with Platelet Lysate 
The preparation of Poly (Gly25-co-HPMA75) based NPs was carried out by co-
precipitation technique. In brief, 12.5 mg of polymer was dissolved in 2 ml of a 
water/ethanol solution (1:4) and was added by a syringe equipped with 22 G needle to a 
solution of 7 mg of GIG-βCD, 5 mg of HSA and 200 µl of PL in 4.8 ml of distilled water 
kept under magnetic stirring at room temperature.  
Preparation of Unloaded Poly (Gly25-co-HPMA75) based nanoparticles in presence of 
Heparin 
The preparation of Poly (Gly25-co-HPMA75) based NPs was carried out by co-
precipitation technique. In brief, 12.5 mg of polymer was dissolved in 2 ml of a 
water/ethanol solution (1:4) and was added by a syringe equipped with 22 G needle to a 
solution of 7 mg of GIG-βCD, 5 mg of HSA and 4 μg of Hp in 5 ml of distilled water 
kept under magnetic stirring at room temperature.    
Preparation of Poly (Gly25-co-HPMA75) based nanoparticles loaded with Platelet Lysate 
in presence of Heparin  
The preparation of Poly (Gly25-co-HPMA75) based NPs was carried out by co-
precipitation technique. In brief, 12.5 mg of polymer was dissolved in 2 ml of a 
water/ethanol solution (1:4) and was added by a syringe equipped with 22 G needle to a 
solution of 7 mg of GIG-βCD, 5 mg of HAS, 200 μl of PL and 4 μg of Hp in 4.8 ml of 
distilled water kept under magnetic stirring at room temperature.     
Preparation of Poly (Gly25-co-HPMA75) based nanoparticles loaded with Fluorescein  
Isothiocyanate Conjugate Human Serum Albumin 
The preparation of Poly (Gly25-co-HPMA75) based NPs was carried out by co-
precipitation technique. In brief, 12.5 mg of polymer was dissolved in 2 ml of a 
water/ethanol solution (1:4) and was added by a syringe equipped with 22 G needle to a 
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solution of 7 mg of GIG-βCD, 4.5 mg of HSA and 0.5 mg of HSA-FITC in 5 ml of 
distilled water kept under magnetic stirring at room temperature. 
4.3.3. Nanoparticles characterization 
Purification of nanoparticles 
The NPs suspensions were purified by using an ALC PK121R refrigerated centrifuge. 
NPs were centrifuge at 8000g for 30 minutes at 4˚C. The obtained pellet of purified NPs 
was resuspended in appropriate media depending on their use. 
Dimensional analysis 
NPs size analyses were carried out by using a Coulter Beckman LS230 Laser Diffraction 
Particle Size Analyzer, equipped with small volume module plus. Samples were added 
into the cell until 30-50% obscuration of PIDS detector. Three runs were performed on 
each sample. 
Morphological analysis  
The NPs morphology was evaluated by scanning electron microscopy (SEM) (JEOL 
LSM5600LV). The samples were prepared from purified and lyophilised NPs. Gold 
sputtering was performed before SEM analysis. 
Freeze-drying 
After freezing at –20 °C, nanoparticles were lyophilised in 5 Pascal Lio 5P lyophilisator, 
equipped with RV8 (Edwards) vacuum pump.  
Determination of protein encapsulation efficiency and loading 
Proteins encapsulation efficiency was calculated from the proteins amount that was 
detected in the supernatant recollected after centrifugation of the NPs samples. Standard 
micro BCA protein assay was used to determine the amount of free proteins (HSA or 
HSA-FITC) in the NPs supernatant and the amount of proteins contained in the PL 
employed for the NPs preparation. The difference between the amount of protein 
employed for the NPs preparation, and the amount of proteins measured in NPs 
supernatant represented the proteins loaded into NPs. This value was necessary for the 
calculation of the encapsulation efficiency and drug loading. The encapsulation 
efficiency was calculated as percentage of proteins loaded in the NPs with respect to 
total amount of proteins added during the formulation of NPs (Equation 1). Drug loading 
was calculated as percentage of proteins loaded in NPs with respect to the dry weight of 
recovered NPs (Equation 2) [21]. A calibrations curve of Bovine Serum Albumin (BSA) 
was prepared by following the manufacturer instructions. All samples were measured at 
565 nm. Mean values were obtained from three different batches. 
Chapter IV: Poly (Gly25-co-HPMA75) based Nanoparticles Loaded with Platelet Lysate 
 
92 
 
 
Equation 1: 
 
 
Equation 2:  
 
 
Stability studies of nanoparticles  
Stability of unloaded and PL loaded NPs, prepared in absence and presence of Hp, was 
studied in water medium by dynamic light scattering using Coulter Beckman LS230 
Laser Diffraction Particle Size Analyzer. NPs suspensions were stored under static 
conditions at 4˚C. The average size was analyzed at specified time intervals.   
In vitro HSA-FITC release kinetics from Poly (Gly25-co-HPMA75) nanosystems  
The HSA-FITC loaded NPs were purified by centrifugation and the resulting pellet was 
resuspended in 7ml of PBS 1X. Purified NPs suspension was divided into aliquots of 
1ml into individual tube and incubated at 37˚C under magnetic stirring. At different time 
points, samples were centrifuged at 8000g for 15 minutes at room temperature and the 
obtained supernatants were collected. The released HSA-FITC concentration in the 
collected supernatants was assessed spectrofluorimetrically with excitation and emission 
wavelengths of 485 and 535nm, respectively. 
Incorporation of nanoparticles into fibrin matrix  
The fibrin matrix kit consisted of thrombin and fibrinogen in separate vials, plus separate 
solutions of calcium chloride (CaCl2) and potassium dihydrogen phosphate (KDP). The 
PL loaded NPs incorporated fibrin gel was prepared as follows. Thrombin was 
reconstituted in a CaCl2 solution and then drawn into a syringe. Fibrinogen, containing 
Factor XIII, was reconstituted in the KDP solution in order to obtain 30 IU/ml of 
fibrinogen concentration and then 3 mg of PL loaded NPs were added to this suspension. 
The PL-NPs-fibrinogen suspension was kept under magnetic stirring until the complete 
dissolution of NPs. The NPs- fibrinogen suspensions were placed respectively into 24-
well plate and when the thrombin solution was added, the gelification phenomenon 
occurred immediately due to the conversion of fibrinogen to fibrin, and the plate was 
incubated at 37 ˚C for 1 h to complete polymerization. The fibrin matrices were prepared 
with two different concentrations of thrombin, 625 UI/ml and 100 UI/ml respectively, in 
order to study the effect of thrombin concentrations on the fibrin matrix formation.  
Antonella Lisella PhD Thesis 
93 
 
4.3.4. Biological investigations  
Absorbance measurements on microplates 
Microplate absorbance measurements were performed by means of Benchmark Bio–Rad 
Microplate Reader. All data were processed by using Microplate Manager III (Biorad) 
and Igor Pro (Wavemetrics). 
CO2 incubator 
Cell cultures were performed in a Hera Cell (Heraeus Instruments S.p.A.) CO2 Incubator 
in 5% CO2 enriched atmosphere.  
Laminar flow cabinet 
Experiments that required sterile conditions were performed under a Hera Safe HS12 
Bioclass II (Heraeus Instruments S.p.A.) laminar flow cabinet. 
Optical Microscopy (OM)  
Optical microscopy observations were performed by Nikon Eclipse TE 2000 inverted 
microscope equipped with epifluorescence lamp and Nikon D Eclipse C1 confocal 
system. 
Determination of IC50 of unloaded Poly (Gly25-co-HPMA75) based nanoparticles 
For the determination of the IC50 (50% inhibitory concentration, that is the material 
concentration at which 50% of cell death in respect to the control is observed) of the 
prepared NPs a subconfluent monolayer of 3T3 fibroblast was trypsinized using a 0.25% 
trypsin, 1mM EDTA solution, centrifuged at 200 × g for 5 min, re-suspended in growth 
medium and counted. Appropriate dilution was made in order to obtain 3 ×103 cells per 
100 μl of medium, the final volume present in each well of a 96 well plate. Cells were 
incubated at 37 ˚C, 5% CO2 for 24 h until 60–70% confluence was reached. The medium 
from each well was then removed and replaced with medium containing a different 
concentration (1-10 mg/ml) of unloaded NPs. Control cells were incubated with fresh 
growth medium and wells containing only growth medium were used as blanks. After 
24h of incubation with medium containing the NPs sample, cells were analyzed for 
viability with Cell Proliferation Reagent WST-1. 
 
Determination of IC50 of Platelet Lysate loaded Poly (Gly25-co-HPMA75) based 
nanoparticles 
For the determination of the IC50 of PL loaded NPs a subconfluent monolayer of 3T3 
fibroblast was trypsinized using a 0.25% trypsin, 1mM EDTA solution, centrifuged at 
200×g for 5 min, re-suspended in growth medium and counted. Appropriate dilution was 
Chapter IV: Poly (Gly25-co-HPMA75) based Nanoparticles Loaded with Platelet Lysate 
 
94 
 
made in order to obtain 3 ×103 cells per 100 μl of medium, the final volume present in 
each well of a 96 well plate. Cells were incubated at 37 ˚C, 5% CO2 for 24 h until 60–
70% confluence was reached. The medium from each well was then removed and 
replaced with medium containing a different concentration (1-10 mg/ml) of PL loaded 
NPs. Control cells were incubated with fresh growth medium and wells containing only 
growth medium were used as blanks. After 24h of incubation with medium containing 
the NPs sample, cells were analyzed for viability with Cell Proliferation Reagent WST-
1.  
4.4. Results and Discussion 
The preparation of bioeliminable polymeric NPs for drug delivery were carried out by 
using the co-precipitation technique. Co-precipitation is an original technique developed 
in our laboratory. Co-precipitation is based on the dropwise addition of an organic 
polymer solution to an aqueous protein solution under gentle magnetic stirring; the 
progressive interaction between the two components gives rise to the formation of a NPs 
suspension. In comparison to similar methods for NPs preparation, the co-precipitation 
method does not imply the use of chlorinated solvents or energetic mixing, both of which 
are known to cause appreciable protein denaturation [11] [22]. This method turned out to 
be particularly suitable for the preparation of nanocarriers for protein drugs delivery.  
 Preparation and characterization of Poly (Gly25-co-HPMA75) based NPs  
The co-precipitation technique described above yields both unloaded (blank) and PL 
loaded NPs in presence and absence of Hp. In all formulations, NPs were characterized 
by narrow monomodal distribution an average diameter size below 200 nm (Table 1). 
The diameters were not affected by the addition of Hp (Figure 2). The obtained size 
represents a good characteristic for further applications of these NPs, because this 
diameter size fall within the limit size of 220 nm approved by the Food and Drug 
Administration (FDA) for NPs administered by injection [23]. Furthermore, NPs with 
diameters ranging from 100 to 200 nm are characterized by high cellular uptake since 
they can easily cross the physiological barriers and have access to different cell districts 
[24, 25]. 
SEM analysis of the purified and lyophilized solid pellets showed a homogeneous 
distribution of spherical NPs (Figure 3). The nanosystems prepared in absence and 
presence of Hp did not show appreciable differences.   
PL loaded NPs prepared in absence of Hp were characterized by encapsulation 
efficiency (EE %) of 55 ± 6 % and PL loading of 5.6 ± 0.9 %. In presence of Hp, the EE 
% of PL was 68 ± 2.5% and PL loading was 7.2 ± 3.3 %. The increase of in EE % and 
loading % can be attributed to the presence of Hp, which gave stability to PL and 
improved its encapsulation into NPs. It has been demonstrated that Hp in solution can 
bind GFs by ionic interactions [26] and the formation of these Hp-GFs complexes might 
have increased the GFs encapsulation into NPs [27].   
Antonella Lisella PhD Thesis 
95 
 
Based on these results, the NPs formulations prepared in presence of Hp were chosen for 
the following set of analysis.   
 
Figure 2: Diameter distribution of Poly (Gly25 -co-HPMA75) based NPs. Unloaded NPs (A) and 
loaded with PL (B). In C and D are shown NPs prepared with heparin unloaded and loaded with 
PL respectively. 
 
 
 
 
 
 
Table 2: Dimensional analysis of Poly (Gly25-co- HPMA75) based NPs. 
Table 2 
Size ± S.D. 
(nm) 
Unloaded NPs 135 ± 19 
PL loaded NPs 111 ± 15 
Unloaded NPs with 
Heparin sodium salt 
111 ± 15 
PL loaded NPs with 
Heparin sodium salt 
125 ± 18 
Chapter IV: Poly (Gly25-co-HPMA75) based Nanoparticles Loaded with Platelet Lysate 
 
96 
 
 
Figure 3: Morphological analyses (SEM micrograph) of Poly (Gly25 -co-HPMA75) based NPs. 
Unloaded NPs (A) PL loaded NPs (B), unloaded with heparin (C) and PL heparin loaded NPs (D). 
NPs Stability Studies  
NPs stability is one the most critical issues for their applications to biological systems, as 
their general tendency is to aggregate upon storage. In these studies we analyzed the 
stability of unloaded and PL loaded NPs, prepared in absence and presence of Hp. NPs 
were stored in aqueous medium at 4°C by monitoring their size for 4 weeks. The results 
shown in Figure 4 indicated that all formulations maintained their size below 200 nm 
and remain stable in water for 4 weeks.  
 
Figure 4: Stability analyses of unloaded and PL loaded Poly (Gly25-co-HPMA75) based NPs 
prepared in absence and presence of Hp in water medium. 
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Preparation and characterization of HSA-FITC loaded Poly (Gly25-co-HPMA75) based 
NPs  
The drug release profile of Poly (Gly25-co-HPMA75) based NPs was evaluated by using 
HSA-FITC as model protein. HSA-FITC loaded NPs were prepared and characterized in 
terms of size and morphology. The morphological analysis of the purified and 
lyophilized solid pellets showed that spherical homogeneously distributed HSA-FITC 
loaded NPs were successfully prepared (Figure 5/A). Dimensional analysis carried out 
by light scattering showed that NPs dispersions were constituted of monodispersed 
nanoparticles having an average diameter of 125 ± 79 nm (Figure 5/B) and an HSA-
FITC EE% of the 85 ± 2.6%. The physical properties of HSA-FITC loaded NPs were 
comparable to that of PL loaded NPs, thus making this protein a good model for the 
study of the in vitro release kinetics of proteins from Poly (Gly25-co-HPMA75) based 
NPs. 
 
Figure 5: SEM image of HSA-FITC loaded Poly (Gly25-co-HPMA75) based NPs (A). Diameter 
distribution of HSA-FITC loaded Poly (Gly25-co-HPMA75) based NPs (B). 
 
In vitro HSA-FITC release kinetics from Poly (Gly25-co-HPMA75) nanosystems  
The experimental conditions to evaluate the protein release profile were set up in order 
to reproduce the physiological environment in terms of temperature, pH and salt 
concentrations. A PBS 1X pH 7.4 was chosen as experimental medium because of its 
buffer strength, during NP release studies [11].  
The in vitro protein release profile from NPs is shown in Figure 6. HSA-FITC release 
from NPs was characterized by an initial burst of 30 % followed by a sustained release 
of 70 % in 3 days. The burst release might be attributed to the fraction of the protein 
which is adsorbed or weakly bound to the NPs surface. After this first release phase, the 
release of HSA-FITC was almost completed in 3 days. This fast release was what we 
expected for this formulation that should be incorporated into a fibrin matrix and then 
subcutaneously injected into the ischemic limbs.   
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Figure 6: HSA-FITC release profile from Poly (Gly25-co-HPMA75) based NPs. 
 
Incorporation of nanoparticles into fibrin matrix  
In order to obtain injectable or implantable systems for the treatment of ischemic 
diseases, fibrin gels loaded with the developed PL-NPs were prepared. Gels were 
obtained by using two different concentrations of thrombin (Figure 7). The gelification 
phenomenon occurred immediately due to the conversion of fibrinogen into fibrin and 
PL-NPs were successfully entrapped into the matrices.  
The composition of fibrin gel, in terms of fibrinogen and thrombin concentrations, 
represents an important parameter for the release rate of fibrin matrices [28]. In fact, the 
release can be controlled by adjusting the content of thrombin or fibrinogen. As the 
concentration of thrombin is increased in the composite gel, a dense cross-linked fibrin 
network is formed, and the release from the fibrin network is slowed [29].  
We examined the effect of thrombin concentrations on the PL-NPs-loaded fibrin gel 
formation in order to obtain fibrin matrices with different release properties. No 
significant difference in fibrin matrices formation were observed between the two 
preparations with different thrombin concentrations; the prepared fibrin matrices resulted 
equally suitable to be used as devices for PL-NPs incorporation, thus offering the 
possibility to modulate the PL release at a desired rate.  
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Figure 7: Fibrin matrices with PL loaded poly (Gly25-co-HPMA75) based NPs prepared with 625 
UI/ml (A) and 100 UI/ml (B) of thrombin respectively. 
Determination of IC50 of Poly (Gly25-co-HPMA75) based nanoparticles 
In order to evaluate the biocompatibility of NPs, in vitro experiments were carried out 
using the balb 3T3 mouse embryo fibroblasts clone A31 cell line, following the 
procedures of ISO 10993 - Part 5: “Test for cytotoxicity - in vitro methods”. 
Cytotoxicity, defined as the “in vitro evaluation of toxicological risks using cell culture”, 
is a rapid, standardized, sensitive and inexpensive way to assess the in vitro 
biocompatibility of materials to be used in biomedical applications [30]. The prepared 
Poly (Gly25-co-HPMA75) based NPs were easily re-suspended in DMEM, thus allowing 
for the investigation of their IC50. The NPs were suspended in DMEM at different 
concentrations ranging between 1 and 10 mg/ml. Cells were incubated for 24h with NPs 
and then tested for cell viability using WST-1 tetrazolium salt assay. The obtained 
results, reported in Figure 7, showed that the NPs formulations did not exhibit significant 
cytotoxic effects. The IC50 values were higher than 10 mg/ml, with no considerable 
difference between the unloaded and PL loaded NPs. In fact, several studies 
demonstrated that PL is not toxic and it can be used in cell culture as substitute of Fetal 
Bovine Serum (FBS). PL contains a number of growth promoting substances, including 
GFs, which makes it an attractive as alternative medium for cell culture [31];[32].   
 
 
Figure 7: Cell viability measured by WST-1 assay in A31 cell line in presence of increasing 
concentrations of unloaded Poly (Gly25-co-HPMA75) based NPs (A) and PL loaded NPs (B). 
Chapter IV: Poly (Gly25-co-HPMA75) based Nanoparticles Loaded with Platelet Lysate 
 
100 
 
4.5. Conclusions  
This study was aimed at the preparation and characterization of Poly (Gly25-co-HPMA75) 
based NPs as carriers for the administration of PL. NPs were successfully prepared by 
the co-precipitation technique, a versatile method that appears advantageous for the 
preparation of nanocarriers loaded with non-conventional drugs such as proteins and 
peptides. Hp was used as stabilizing agent for the NPs preparations, in order to obtain an 
improvement of PL encapsulation and stabilization of the dispersions. All the NPs 
formulations displayed a monomodal distribution of diameters with an average size 
below to 200 nm and good spherical shape. The addition of Hp to the formulations did 
not affect the dimensions and morphologies of the prepared nanosystems. PL was 
successfully encapsulated in the prepared NPs with an EE % of 55 %, which was raised 
to 68 % by adding Hp. Alike, PL loading % raised from 5.6 % to 7.2 % by adding Hp. 
These results demonstrated the capability of Hp to improve the PL encapsulation into 
NPs.  
The stability of the prepared NPs was studied within 4 weeks. The nanosystems showed 
a good stability in water and maintained their size below 200 nm, with no appreciable 
difference between the loaded and unloaded NPs both in presence and absence of Hp. In 
vitro release studies were carried out by using HSA-FITC NPs drug release was 
characterized by an initial burst followed and a sustained release of 3 days. The 
developed NPs were successfully incorporated into fibrin matrices prepared by using two 
different concentrations of thrombin. This system may be useful to achieve a controlled 
release of PL at the ischemic site. Careful in vitro cytotoxicity test performed on NPs 
showed their excellent compatibility. They were characterized by an IC50 higher than 10 
mg/ml and no differences in cell viability were observed between PL loaded and 
unloaded NPs, which highlighted the excellent cytocompatibility of PL. Taking together 
the above results, we believe that the PL loaded Poly (Gly25-co-HPMA75) based NPs 
could be a very promising injectable system for the controlled release of PL for the 
treatment of ischemic diseases.   
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5. Chapter V: Preparation of magnetic core and polymer 
shell nanoparticles using an innovative protein 
biosurfactant  
5.1. Introduction 
Drug delivery technology has emerged as a truly interdisciplinary science aiming at 
improving human health. The basic goal of a controlled drug delivery system (DDS) is to 
deliver a biologically active molecule at a desired rate for a desired duration, to maintain 
the drug level in the site of action within the therapeutic window [1]. The current 
challenges associated with DDS include the specific targeting of active agents at the 
pathological site, in order to avoid large amount of drug administration, non-specific 
toxicity and undesired side-effects [2]. Among the current schemes of drug delivery, a 
promising one employs polymeric nanoparticles (NPs) endowed with magnetic 
proprieties [3]. This technology is based on the co-encapsulation of drugs with magnetite 
(Fe3O4) inside a polymer shell, in order to prepare carriers that can be magnetically 
guided to the desired tissues thus releasing the drug at the target site [4]. 
Polyhydroxyalkanoates (PHAs) are natural aliphatic polyesters, produced by a wide 
range of microorganisms. These biodegradable polyesters are stored intracellularly and 
act as carbon and energy reserve for the cells [5]. PHAs are characterized by good 
biocompatibility and biodegradability [6]. Due to these features, PHAs have been 
investigated as matrices for drug delivery applications and tissue engineering [7]. Over 
the past years, over 150 different types of PHA have attracted medical interest and 
particularly poly-3-hydroxybutyrate (PHB), poly-4-hydroxybutyrate (P4HB), 
copolymers of 3-hydroxybutyrate and 3-hydroxyvalerate (PHBV), copolymers of 3-
hydroxybutyrate and 3-hydroxyhexanoate (PHBHHx) and poly-3-hydroxyoctanoate 
(PHO) [8]. PHBHHx is a good matrix for the preparation of carries loaded with 
hydrophobic drugs since it is basically constituted by an hydrophobic ester backbone and 
alkyl side chains (Figure 1). It is also characterized by good biodegradability and its 
products of degradation are not cytotoxic [9].  
PHAs granules have a phospholipids membrane with embedded and attached proteins 
with regulatory or structural functions. One of the most abundant classes of structural 
proteins in PHAs granules is represented by phasins. This class of proteins is 
characterized by molecular weight ranging between 14 and 28 kDa [10], amphiphilic 
proprieties and the capability to non-specifically bind hydrophobic polymers. Their 
function is to promote PHA biosynthesis, influencing the morphology, number and size 
of PHA granules [11]. Phasins, in several bacterial strains, have been shown to increase 
the production and accumulation of PHAs granules in cells and to provide an interface 
between the hydrophobic granule surface and the aqueous cell cytoplasm [12, 13]. In 
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recent years, phasins have been widely used as stabilizing agent to develop methods for 
protein purification, drug delivery and tissue engineering [14-18].  
Phasin P (PhaP) was successfully employed as a biosurfactant to stabilize emulsions of 
water with lubricating oil, diesel and soybean oil. The results showed that PhaP 
displayed in the emulsions the same stabilizing effects as the other commonly used 
surfactants [19].  
In this study we report some preliminary results on the preparation of magnetite loaded 
NPs by using PhaP as stabilizing agent. Two polymeric materials, PHBHHx and poly 
(lactide-co-glycolide) (PLGA), were employed for the NPs preparation, in order to 
investigate the capability of PhaP to stabilize NPs based on the two employed polymers. 
The prepared nanocarriers were characterized in term of size and Z-potential. The 
presence of magnetite and the morphology of prepared NPs were evaluated by 
Transmission Electron Microscopy (TEM).   
 
Figure 1: Chemical structure of PHBHHx. 
5.2. Material 
PLGA85:15 [lactide:glycolide (85:15); inherent viscosity midpoint of 3.1 dl/g] was 
obtained from Purac-Biochem (Amsterdam, NL). PHBHHx80:20 (Mw 80 KDa) and PhaP 
were kindly provided by Laboratory of Microbiology, Tsinghua University (Beijing, 
China). Magnetite was purchased from Sigma Aldrich (St. Louis, MO). All solvents used 
were commercially available (Beijing Chemical Works, Beijing, China).   
5.3. Methods 
5.3.1. Nanoparticles formulations 
Preparation of PLGA based nanoparticles by emulsification diffusion technique 
Unloaded and magnetite loaded PLGA based NPs were prepared by an emulsification 
diffusion technique [20]. In brief, 15 mg of PLGA were dissolved in 1 ml of DCM and 
then, 5 mg of magnetite were added. This organic phase was sonicated (SCINTZ JY92-
2D ultrasonic cell crusher) (300W/5minutes) to prepare a homogeneous dispersion of 
magnetite; 2 ml of water solution, containing 200 µg of PhaP, were added to the organic 
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phase and the subsequent mixture was emulsified by sonication (300W/5minutes). An 
excess amount of water (5 ml) was added to the o/w emulsion under sonication. After 
solvent evaporation under vacuum at 30˚C NPs were concentrated in aqueous medium.   
Preparation of PLGA based nanoparticles by emulsification solvent-evaporation process  
PLGA based NPs were prepared by an emulsification solvent-evaporation process. 
Briefly, 10 mg of PLGA were dissolved in 1 ml of chloroform to prepare the organic 
phase. The aqueous phase was prepared by dispersing 5mg of magnetite in 10 ml of 
water; the resulting suspension was homogenized by sonication (SCINTZ JY92-2D 
ultrasonic cell crusher) (600W/3min). Following 1.3 mg of PhaP was added, and the 
resulting dispersion was further sonicated (200W/3min). The polymer solution was 
added dropwise with an 18G needle into the aqueous phase. The resulting emulsion was 
sonicated (400W/3min) to reduce the droplet size of the organic phase and stirred at 
room temperature to allow the organic solvent evaporation. The obtained NPs 
suspension was then filtered through a 1μm filter. Unloaded NPs were obtained without 
including the magnetite in the aqueous phase preparation.   
Preparation of PHBHHx based nanoparticles by emulsification solvent-evaporation 
process  
PHBHHx based NPs were prepared by an emulsification solvent-evaporation process. 
Briefly, 10 mg of PHBHHx were dissolved in 1 ml of chloroform to prepare the organic 
phase. The aqueous phase was prepared by dispersing 5mg of magnetite in 10 ml of 
water; the resulting suspension was homogenized by sonication (SCINTZ JY92-2D 
ultrasonic cell crusher) (600W/3min). Following 1.3 mg of PhaP was added, and the 
resulting dispersion was further sonicated (200W/3min). The polymer solution was 
added dropwise with an 18G needle into the aqueous phase. The resulting emulsion was 
sonicated (400W/3min) to reduce the droplet size of the organic phase and stirred at 
room temperature to allow the organic solvent evaporation. The obtained NPs 
suspension was then filtered through a 1μm filter. Unloaded NPs were obtained without 
including the magnetite in the aqueous phase preparation.   
5.3.2. Nanoparticles characterization 
Purification of nanoparticles 
NPs suspensions were purified by using an Eppendorf centrifuge (Model 5424, 
Hamburg, Germany). NPs were centrifuged at 10000g for 15 minutes at 4˚C. The 
obtained pellets of purified NPs were freeze-dried for further analysis.  
Dimensional and Z-potential analysis  
Dynamic light scattering (DLS) was used for size, polydispersity index and Z-potential 
measurements (Zetasizer Nano ZS90, Malvern Instruments Inc., Southborough, MA). 
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The measurements were performed at 25˚C. The viscosity and refraction index of the 
continuous phase were set equal to those specific to water. Z-potential measurements 
were made with a disposable capillary cell with a volume of 1 ml. The values of the size 
and Z- potential were calculated as the mean value of 3 replicates for each NPs 
formulation. 
Morphological analysis  
NPs morphology was evaluated by Transmission Electron Microscopy (TEM, Hitachi H-
7650B; Hitachi, Japan) at an accelerating voltage of 80kV. A drop of sample was 
deposited on the copper grid and air dried before the analysis.   
5.4. Results and Discussion 
In this work we investigated the possibility to prepare magnetite loaded PLGA or 
PHBHHx based NPs by using PhaP as biosurfactant. Preliminary formulation studies 
revealed that the emulsification diffusion technique was not suitable to prepare magnetite 
loaded PLGA based NPs. Indeed, as it is shown in the following results magnetite was 
not entrapped into their matrix. Based on these results, further formulation studies were 
performed by using emulsification solvent-evaporation process. This method turned out 
to be suitable for the preparation of NPs by employing both PLGA and PHBHHx as 
polymer matrix. We also attempted to prepare unloaded and magnetite loaded NPs 
without the addiction of PhaP. However, in absence of this stabilizing agent the 
formation of NPs did not occur.  
Preparation of PLGA based nanoparticles by emulsification diffusion technique 
NPs were prepared with the addition of PhaP as a stabilizing agent. The formation of 
stable colloidal suspensions confirmed that the presence of PhaP was essential for the 
NPs preparation. The prepared nanosystems were characterized by monomodal 
distribution of diameters and negative Z-potential (Figure 2). The Z-potentials of the 
prepared NPs were in the range of -20 mV, and there were no significant difference in 
surface charge between the unloaded and magnetite loaded NPs. Table 1shows the NPs 
diameter size, polydispersity index (PI) and Z-potential values. The PI of prepared NPs 
confirmed that the nanosystems were monodispersed. In fact, PI is a parameter to define 
the particle size distribution, and NPs characterized by PI less than 0.7 displays narrow 
size distribution [21]. The addition of magnetite to the system increased the size of the 
PLGA prepared NPs. However, this increase in size cannot be attributed to an effective 
encapsulation of magnetite into the NPs since, as highlighted by the TEM image (figure 
3/B), magnetite (black dots) was just surrounding the NPs but not entrapped into their 
matrix. Figure 3 shows unloaded NPs that were characterized by spherical morphology.  
Based on these results, further formulation studies were carried out in order to efficiently 
encapsulate magnetite inside the NPs.  
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Figure 2: Characterization of PLGA based NPs. Diameter distributions of unloaded NPs (A) and 
magnetite loaded NPs (B). Z-potential of unloaded NPs (C) and magnetite loaded NPs (D). 
Table 1 
Particle average size 
Z-Potential  
average 
Distribution 
Size ± S.D. 
(nm) 
Polydispersity 
Index (PI ± 
S.D.) 
(mV) ± Zeta 
Deviation 
Unloaded PLGA 
based NPs 
Monomodal 220 ± 0.5 0.160 ± 0.01 -19 ± 4.14 
Fe3O4 loaded 
PLGA based NPs 
Monomodal 311 ± 3.8 0.203 ± 0.01 -23 ± 4.26 
 
Table 1: Size analysis, polydispersity index and Z-potential of PLGA based NPs. 
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Figure 3: Morphological analyses (TEM micrograph) of PLGA based NPs. Unloaded NPs (A). 
Magnetite loaded NPs, the black dots represent the magnetite (B). 
Preparation of PLGA based nanoparticles by emulsification solvent-evaporation process 
The physical-chemical characterizations of the prepared NPs are reported in Table 1. The 
prepared nanosystems, both unloaded and loaded with magnetite, were characterized by 
monomodal distribution of diameters and negative Z-potential values (Figure 4). The 
presence of magnetite did not affect the size and Z-potential of prepared NPs and their 
size was around of 200 nm with a good PI. Likely, the negativity of Z-potential (below -
20 mV) was due to the presence of terminal carboxylic groups on the PLGA chains [22]. 
PhaP probably did not contribute to the NPs surface charge since the pI of the protein is 
5.6 [23] and it is not charged at the pH (~ 5.5) of the NPs formulation.  
Table 2 
Particle average size 
Z-Potential  
average 
Distribution 
Size ± S.D. 
(nm) 
Polydispersity 
Index (PI ± 
S.D.) 
(mV) ± Zeta 
Deviation 
Unloaded PLGA 
based NPs 
Monomodal 186 ± 8.8 0.101 ± 0.003 -25 ± 5.56 
Fe3O4 loaded 
PLGA based NPs 
Monomodal 147 ± 46 0.340 ± 0.133 -21 ± 4.55 
 
Table 2: Size analysis, polydispersity index and Z-potential of PLGA based NPs. 
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Figure 4: Characterization of PLGA based NPs. Diameter distributions of unloaded NPs (A) and 
magnetite loaded NPs (B). Z-potential of unloaded NPs (C) and magnetite loaded NPs (D). 
TEM was used to investigate the morphology of the prepared nanosystems and to gain 
qualitative information on the encapsulation of magnetite into NPs. Figure 5 shows that 
the NPs were characterized by spherical morphology and confirmed the presence of 
magnetite into the core of the particles. Likely, the black dots (Figure 5/B) correspond to 
the magnetite embedded into the polymer matrix.  
 
Figure 5: TEM images of PLGA based NPs. Unloaded NPs (A) and magnetite (black dots) loaded 
NPs (B). 
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Preparation of PHBHHx based nanoparticles by emulsification solvent-evaporation 
process 
Based on the results obtained by using PLGA, the emulsification solvent-evaporation 
process was employed for the preparation of PHBHHx based NPs. Table 1 shows the 
physical-chemical features of prepared NPs. The unloaded and magnetite loaded NPs 
were characterized by monomodal distribution of diameters (Figure 6A/B) with an 
average diameter size of 150 nm. The narrow diameter distributions were confirmed by 
the PI, below to 0.2 in both NPs formulations. The prepared NPs displayed a negative Z-
potential value (Figure 6), around -30 mV, which was not affected by the presence of 
magnetite and PhaP. This confirmed the same trend observed for PLGA based NPs 
where the presence of PhaP did not contribute to the particles surface charge.  
Table 3 
Particle average size 
Z-Potential  
average 
Distribution 
Size ± S.D. 
(nm) 
Polydispersity 
Index (PI ± 
S.D.) 
(mV) ± Zeta 
Deviation 
Unloaded PHBHHx 
based NPs 
Monomodal 140 ± 0.9 0.156 ± 0.02 -30.3 ± 5.03 
Fe3O4 loaded 
PHBHHx based NPs 
Monomodal 155 ± 1.2 0.185 ± 0.01 -26.7 ± 5.50 
Table 3: Size analysis, polydispersity index and Z-potential of PHBHHx based NPs. 
 
Figure 6: Characterization of PHBHHx based NPs. Diameter distributions of unloaded NPs (A) 
and magnetite loaded NPs (B). Z-potential of unloaded NPs (C) and magnetite loaded NPs (D). 
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The morphology of PHBHHx based NPs was determined by TEM. Figure 7 shows that 
the NPs were characterized by spherical shape. In figure 7/B, the presence of black dots 
could be attributed to the presence of magnetite, that appeared to be homogeneously 
distributed within the NPs.  
Preliminary investigations of the magnetic property of the NPs was carried out by 
applying an external magnetic field outside of vial containing a suspension of PHBHHx 
based NPs loaded with magnetite. Figure 8/A shows the suspended NPs in water and 
Figure 8/B the NPs attracted aside by a magnet. 
 
Figure 7: TEM micrographs of PHBHHx based NPs unloaded (A) and loaded with magnetite (B). 
 
Figure 8: Picture showing the magnetite loaded PHBHHx based NPs dispersed in water (A) and 
NPs separated from suspension in response to an external magnetic field (B).  
5.5. Conclusions  
This work focused on the preparation of NPs loaded with magnetite by using the small 
bacterial protein PhaP as biosurfactant. PLGA and PHBHHx were selected as polymer 
matrices for NPs preparations. These preliminary results showed that PhaP was essential 
for NPs preparation. In fact, the formation of NPs did not occur in absence of PhaP. 
Moreover, PhaP was able to stabilize the NPs based on either PLGA or PHBHHx, 
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confirming that PhaP binds unspecifically hydrophobic polymers. The emulsification 
diffusion technique was employed for the preparation of PLGA based NPs. The prepared 
NPs were characterized by submicron size and good spherical shape. However, by using 
this method, the magnetite was not encapsulated into the PLGA NPs. Thus an 
emulsification solvent-evaporation process was investigated for the preparation of 
colloidal systems based on PLGA or PHBHHx. The developed NPs were preliminary 
characterized in term of size, Z-potential and morphology. The prepared PLGA or 
PHBHHx NPs displayed submicron size (below to 200 nm), narrow monomodal 
diameter distributions and negative Z-potential values. The NPs surface charge was not 
due to the presence of PhaP, which is not charged at the NPs formulation pH. The 
presence of magnetite did not affect the physical-chemical characteristics of both NPs 
formulations. TEM analysis showed that the NPs were characterized by spherical 
morphology. In addition, the black dots, visible in the TEM images, indicated that 
magnetite might be loaded into the core of the PLGA and PHBHHx based NPs.  
These preliminary results suggest that PhaP can be used as biosurfactant for NPs 
preparation, reducing the costs of production, since it is easily and cost effectively 
produced by recombinant microorganisms.  
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6. Chapter VI: Overall Conclusive Remarks 
The present PhD thesis comprises the implementation of different experimental activities 
performed at the Laboratory of Bioactive Polymer Materials for Biomedical and 
Environmental Applications (BIOLab) of the Department of Chemistry and Industrial 
Chemistry of the University of Pisa and those developed during a six months period 
spent at the Laboratory of Microbiology, School of Life Sciences, Tsinghua University 
(Beijing, China).     
6.1. PLGA based Nanoparticles Loaded with Growth Factors 
During this research activity we developed growth factors (GFs) loaded NPs in order to 
obtain new delivery systems for the treatment of ischemic diseases. In particular, bFGF 
and VEGF were selected for their essential role in the improvement of new blood vessels 
formation, and PLGA was selected as a polymer matrix due to its good biodegradability, 
biocompatibility and low toxicity. Heparin (Hp) and human serum albumin (HSA) were 
used as stabilizing agents for the NPs preparation. As reported by the literature, GFs 
present in their architecture an heparin-binding domain and the interaction of Hp with 
GFs has shown to potentiate its activity and to protect them from heat and enzymatic 
degradation. HSA was selected as a second stabilizing agent due to its amphiphilic 
properties. Indeed, the presence of HSA avoids the interaction of GFs with the organic 
solvent during the NPs formulations, thus protecting them against degradation.  
The prepared NPs were characterized by size, morphology and Z-potential values 
suitable for their future applications. No appreciable differences, in term of the above 
mentioned features, were observed between the unloaded and GFs loaded NPs. As 
exception, the Z-potential value of the GFs loaded NPs was significantly decreased 
confirming the interaction between Hp and GFs. ELISA assays were performed to 
determine the encapsulation efficiency of bFGF and VEGF into NPs. The results showed 
that a high encapsulation efficiency, corresponding to 75% and 95% for bFGF and 
VEGF respectively, was achieved. The successful co-encapsulation of both bFGF and 
VEGF might result in a synergic proangiogenic activity, important for the future 
application of these NPs in the treatment of ischemic conditions. 
6.2. PLGA based Nanoparticles Loaded with Platelet Lysate 
Platelet lysate (PL) is a haemoderivative rich in GFs deriving from the lysis of platelets 
and it is currently investigated in clinical practice for the treatment of several ischemic 
conditions. In this research study, we designed and developed PLGA based NPs loaded 
with PL. The advantage of using PL, instead of recombinant GFs, is that it provides a 
mixture of autologous GFs in their biological concentration, able to promote 
vascularization with greater similarity to the natural process. NPs were successfully 
prepared by a modified solvent diffusion technique, and Hp was used as stabilizing agent 
for their preparation. The developed nanosystems were characterized by monomodal 
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distribution of the diameters, submicron size (below to 200 nm), negative Z-potential 
values and good spherical shape. The results showed a PL encapsulation efficiency and 
loading of about 75% and 2% respectively. In order to specifically evaluate the effect of 
Hp on the GF encapsulation efficiency, we selected PDGF-AB as reference. PDGF-AB 
encapsulation efficiency (EE %) was investigated by ELISA assay, and we observed an 
increase of EE% from 14% to 30%. The prepared nanosystems displayed good stability 
in water medium within 4 weeks. The in vitro release study, performed by using HSA-
FITC as model protein, revealed that under physiological conditions the developed NPs 
release their proteic content in 13 days. Taking into account all these features, the 
developed nanosystems can be considered very promising PL delivery systems for the 
treatment of wound healing. The prepared nanosystems were successfully incorporated 
into a fibrin matrix in order to prepare an active wound dressing with proangiogenic 
properties for topical treatments. 
6.3. Poly (Gly25-co-HPMA75) based Nanoparticles Loaded with 
Platelet Lysate 
In this study PL loaded Poly (Gly25-co-HPMA75) based NPs were successfully prepared 
by co-precipitation technique. The co-precipitation technique is an original procedure 
developed by the research group involved in the present study. NPs displayed a 
monomodal distribution of diameters with an average size below 200 nm and good 
spherical shape. Hp was used as stabilizing agent for the NPs preparation, in order to 
obtain an improvement of PL encapsulation and stabilization of the dispersions. In fact, 
NPs showed a PL encapsulation efficiency of 55 %, which was raised to 68 % by adding 
Hp. The addiction of Hp also improved the PL loading % that rose from 5.6 % to 7.2 %. 
In vitro release studies were carried out by using HSA-FITC as model protein, under 
physiological conditions, and the results showed that NPs release kinetic was 
characterized by an initial burst followed by a sustained release of 3 days. PL loaded 
Poly (Gly25-co-HPMA75) NPs were characterized by excellent proprieties: they were 
stable in aqueous medium within 4 weeks, and displayed a good cytocompatibility with 
an IC50 higher than 10 mg/ml. Overall the obtained results suggest that PL loaded Poly 
(Gly25-co-HPMA75) based NPs could be a very promising injectable system for the 
treatment of ischemic diseases. The developed NPs were successfully incorporated into 
fibrin matrices in order to obtain subcutaneously injectable systems for the treatment of 
ischemic conditions, such as peripheral vascular diseases.   
6.4. Preparation of magnetic core and polymer shell nanoparticles 
using an innovative protein biosurfactant  
Polyhydroxyalkanoates (PHAs), a class of biodegradable polyesters produced by many 
bacteria grown under unbalanced conditions, have been proposed in the last years as 
polymer matrices for the preparation of drug delivery systems due to their excellent 
biocompatibility. Surrounding the PHAs granules, many proteins with different functions 
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were found. The function of one of these proteins, phasin P (PhaP), consists in the 
stabilization of the polymer granules, providing an interface between the hydrophobic 
granules surface and the aqueous cell environment. Based on this knowledge, in this 
study we reported some preliminary results on the preparation of magnetite loaded NPs 
by using PhaP as stabilizing agent. The developed NPs, prepared with two different 
polymeric materials, PLGA and Poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) 
(PHBHHx) showed that the presence of PhaP was essential for NPs preparation.  In fact, 
the formation of NPs did not occur in absence of PhaP. Both PLGA and PHBHHx based 
NPs were characterized by submicron size (below to 200 nm), narrow monomodal 
diameter distributions and negative Z-potential values. TEM analysis showed that the 
NPs were characterized by spherical morphology and indicated that magnetite might be 
loaded into the core of the PLGA and PHBHHx based NPs. These preliminary results 
suggest that PhaP can be effectively used as biosurfactant for NPs preparation. 
 
Antonella Lisella PhD Thesis  
120 
 
ACKNOWLEDGEMENTS  
 
The present PhD thesis work was performed within the framework of two research 
projects, one projects funded by the Tuscany Region: “Biosurgery – Nanostructured 
materials based on fibrin and platelet factors able to promote angiogenesis” and a project 
funded by the European Community, entitled “Hyaluronan-based injectable material for 
tissue engineering” (Hyanji scaffold). 
I would like to first thank my supervisor Dr. Federica Chiellini, who has been a vast 
source of information and direction. I am grateful that she introduced me into this 
fascinating field of science and for her constant guidance, support, and advices that have 
been a vital part for the completion of my research. I am extremely thankful also to Prof. 
Emo Chiellini for his suggestions, support and his kind interest in my research project.  
I would also like to thank my tutor Dr. Cesare Errico, I am grateful for his understanding 
and support during the past three years.   
I would like to thank all my colleagues in this wonderful group for not only the valuable 
suggestions on my research, but also the precious time we spent together. Thank you for 
all of your support and friendship. I absolutely enjoyed these past three years! 
Part of the reported research activities have been performed at Laboratory of 
Microbiology, School of Life Sciences, Tsinghua University (Beijing, China) and I 
would like to thank Prof. George Guo-Qiang Chen and his group members, for their 
assistance and helpful insights in my research.  
My special thanks also to Lakshmi Tripathi, Ruiyan Wang, Hongkun & All microbes 
and all the people that I met in Beijing (Marta, Yuta, Alba, Maggie, Megumi, Brian, 
Caarn, Ewan, Christopher, Filippo, Jason, Long, Lhamo, Richard, Shan and last but not 
least, I would like to thank Takanori). You will always have a special place in my heart. 
I would like to thank all my friends. Their kindness and positive attitude toward life also 
touched me and inspire me to become a better person. I would like to express my 
gratitude to all of them, realizing that most of the things for which I am most grateful, I 
cannot put into words. I give to Mariarita my utmost gratitude and I will remember 
everything you have done for me always, I cannot spend a day without talking to you 
and I cannot imagine my life without you. Special thanks also to Cristina and Daiana, I 
know I could always count on you. Thanks for being the sisters I never had.  
I am really grateful to all of my family for their caring, understanding and support. My 
beloved parents and my brother have been my greatest supporters. It is their 
unconditional love that encouraged me at any time. It is never enough to express my 
gratitude to them.  
Antonella Lisella PhD Thesis 
121 
 
 
APPENDIX 
 
Publications 
Paola Losi, Enrica Briganti, Cesare Errico, Antonella Lisella, Elena Sanguinetti, 
Federica Chiellini, Giorgio Soldani "Fibrin-based scaffold incorporating VEGF and 
bFGF loaded nanoparticles stimulates wound healing in diabetic mice". Submitted to 
Acta Biomaterialia, 2012 
 
Contributions in National and International Conferences and Workshops  
Antonella Lisella, Cesare Errico, Maria Chiara Barsotti, Paola Losi, Angela Magera, 
Claudio Farina, Rossella Di Stefano, Giorgio Soldani, Federica Chiellini “Polymeric 
Nanoparticles for the Controlled Administration of Platelet Lysate” Workshop on: 
Nanotechnologies for HealthCare, Trento, Italy, May 25-26, 2012   
Maria Chiara Barsotti, Federica Chiellini, Antonella Lisella, Cesare Errico, Silvia 
Burchielli, Giorgio Soldani , Rossella Di Stefano "Polymeric Nanoparticles For 
Controlled Delivery Of Platelet Lysate In Ischemic Tissue" 73rd National Congress of the 
Italian Society of Cardiology Rome, December 15-17, 2012  
 
 
 
 
 
 
 
 
 
 
 
Antonella Lisella PhD Thesis  
122 
 
 
 
